Revvity (RVTY) 10-Q 4 Nov 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 28, 2014	Oct. 30, 2014
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Document Period End Date	28-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Amendment Flag	'false	'
Entity Registrant Name	'PERKINELMER INC	'
Entity Central Index Key	'0000031791	'
Current Fiscal Year End Date	'--12-28	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	112,962,552
Entity Well-known Seasoned Issuer	'Yes	'
Entity Voluntary Filers	'No	'
Entity Current Reporting Status	'Yes	'

Condensed_Consolidated_Income_

Condensed Consolidated Income Statements (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Sales Revenue, Goods, Net	$365,933	$355,745	$1,113,027	$1,076,389
Sales Revenue, Services, Net	176,116	166,355	515,802	489,327
Revenue	542,049	522,100	1,628,829	1,565,716
Cost of Goods Sold	190,041	192,247	580,974	569,143
Cost of Services	108,699	96,585	320,849	297,201
Cost of sales	298,740	288,832	901,823	866,344
Selling, general and administrative expenses	142,997	142,780	442,687	441,015
Research and development expenses	30,444	31,410	90,175	99,812
Restructuring and lease charges, net	11,092	1,124	13,969	23,681
Operating income from continuing operations	58,776	57,954	180,175	134,864
Interest and other expense, net	10,966	12,340	31,219	37,245
Income from continuing operations before income taxes	47,810	45,614	148,956	97,619
Provision for income taxes	4,912	4,851	19,104	-3,193
Net income from continuing operations	42,898	40,763	129,852	100,812
Loss from discontinued operations before income taxes	-1,091	-758	-4,205	-2,103
Gain (Loss) on disposition of discontinued operations before income taxes	-7	-64	-381	457
(Benefit from) provision for income taxes on discontinued operations and dispositions	-477	-257	-1,725	-1,173
Net income (loss) from discontinued operations and dispositions	-621	-565	-2,861	-473
Net income	$42,277	$40,198	$126,991	$100,339
Basic earnings (loss) per share:	'	'	'	'
Net income from continuing operations (per share)	$0.38	$0.36	$1.15	$0.90
Net income (loss) from discontinued operations and dispositions (per share)	($0.01)	($0.01)	($0.03)	$0
Net Income (per share)	$0.38	$0.36	$1.13	$0.89
Diluted earnings (loss) per share:	'	'	'	'
Net income from continuing operations (per share)	$0.38	$0.36	$1.14	$0.89
Net income (loss) from discontinued operations and dispositions (per share)	($0.01)	$0	($0.03)	$0
Net income (per share)	$0.37	$0.36	$1.12	$0.88
Weighted average shares of common stock outstanding:	'	'	'	'
Basic (in shares)	112,646	111,827	112,662	112,285
Diluted (in shares)	113,759	113,115	113,836	113,516
Cash dividends per common share	$0.07	$0.07	$0.21	$0.21

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Net income	$42,277	$40,198	$126,991	$100,339
Other Comprehensive Income (Loss), Net of Tax [Abstract]	'	'	'	'
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax	-32,936	16,407	-29,596	1,703
Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Net of Tax	0	299	0	897
Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, Net of Tax	-12	40	-42	10
Other Comprehensive Income (Loss), Net of Tax	-32,948	16,746	-29,638	2,610
Comprehensive Income, Net of Tax, Attributable to Parent	$9,329	$56,944	$97,353	$102,949

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Sep. 28, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$203,683	$173,242
Accounts receivable, net	427,008	466,749
Inventories, net	281,617	260,858
Other current assets	161,389	140,342
Current assets of discontinued operations	650	3,647
Total current assets	1,074,347	1,044,838
Property, plant and equipment, net:	'	'
At cost	505,905	498,111
Accumulated depreciation	-328,581	-314,923
Property, plant and equipment, net	177,324	183,188
Marketable securities and investments	1,391	1,319
Intangible assets, net	396,466	460,430
Goodwill	2,123,235	2,143,120
Other assets, net	111,898	111,633
Disposal Group, Including Discontinued Operation, Long Lived Assets	1,809	2,184
Total assets	3,886,470	3,946,712
Current liabilities:	'	'
Short-term debt	1,157	2,624
Accounts payable	160,506	166,881
Accrued restructuring and integration costs	22,175	26,374
Accrued expenses	381,354	403,678
Current liabilities of discontinued operations	2,241	3,239
Total current liabilities	567,433	602,796
Long-term debt	858,578	932,104
Long-term liabilities	397,705	417,325
Total liabilities	1,823,716	1,952,225
Commitments and contingencies (see Note 18)	'	'
Stockholders' equity:	'	'
Preferred stock-$1 par value per share, authorized 1,000,000 shares; none issued or outstanding	0	0
Common stock-$1 par value per share, authorized 300,000,000 shares; issued and outstanding	112,962	112,626
Capital in excess of par value	114,225	119,906
Retained earnings	1,787,614	1,684,364
Accumulated other comprehensive loss	47,953	77,591
Total stockholders' equity	2,062,754	1,994,487
Total liabilities and stockholders' equity	$3,886,470	$3,946,712

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Sep. 28, 2014	Dec. 29, 2013
Statement of Financial Position [Abstract]	'	'
Preferred stock, par value	$1	$1
Preferred stock, authorized	1,000,000	1,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value	$1	$1
Common stock, authorized	300,000,000	300,000,000
Common stock, issued	112,962,000	112,626,000
Common stock, outstanding	112,962,000	112,626,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013
Operating activities:	'	'
Net income	$126,991	$100,339
Add: net income from discontinued operations and dispositions, net of income taxes	2,861	473
Net income from continuing operations	129,852	100,812
Adjustments to reconcile net income from continuing operations to net cash provided by continuing operations:	'	'
Restructuring and lease charges, net	13,969	23,681
Depreciation and amortization	86,833	95,241
Stock-based compensation	11,769	11,423
Amortization of deferred debt issuance costs	1,071	2,598
Gains on disposition	0	1,566
Amortization of acquired inventory revaluation	0	203
Changes in operating assets and liabilities which provided (used) cash, excluding effects from companies purchased and divested:	'	'
Accounts receivable, net	26,841	27,568
Inventories, net	-28,536	-32,020
Accounts payable	-4,009	-5,514
Accrued expenses and other	-52,133	-134,158
Net cash provided by operating activities of continuing operations	185,657	88,268
Net cash (used in) provided by operating activities of discontinued operations	-624	-1,380
Net cash provided by operating activities	185,033	86,888
Investing activities:	'	'
Capital expenditures	-22,214	-31,554
Proceeds from Life Insurance Policies	490	783
Proceeds from dispositions of property, plant and equipment, net	0	52,202
Payments for acquisitions and investments, net of cash and cash equivalents acquired	-1,879	-7,049
Net cash used in investing activities of continuing operations	-23,603	14,382
Net cash provided by investing activities of discontinued operations	-213	484
Net cash used in investing activities	-23,816	14,866
Financing activities:	'	'
Payments on debt	-305,000	-429,000
Proceeds from borrowings	227,000	419,000
Payments of debt issuance costs	'	0
Payments of Financing Costs	1,845	'
Payments for (Proceeds from) Hedge, Financing Activities	0	1,363
Payments on other credit facilities	-1,225	5,530
Payments for acquisition-related contingent consideration	-855	0
Proceeds from stock options exercised	20,947	15,292
Purchases of common stock	-39,004	-127,186
Dividends paid	-23,713	-23,733
Net cash (used in) provided by financing activities	-123,695	-138,734
Effect of exchange rate changes on cash and cash equivalents	-7,081	-2,161
Net (decrease) increase in cash and cash equivalents	30,441	-39,141
Cash and cash equivalents at beginning of period	173,242	171,444
Cash and cash equivalents at end of period	$203,683	$132,303

Basis_of_Presentation

Basis of Presentation	9 Months Ended
	Sep. 28, 2014
Accounting Policies [Abstract]	'
Basis of Accounting [Text Block]	'
	Basis of Presentation
	The condensed consolidated financial statements included herein have been prepared by PerkinElmer, Inc. (the “Company”), without audit, in accordance with accounting principles generally accepted in the United States of America (the “U.S.” or the "United States") and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Certain information in the footnote disclosures of the financial statements has been condensed or omitted where it substantially duplicates information provided in the Company’s latest audited consolidated financial statements, in accordance with the rules and regulations of the SEC. These condensed consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and notes included in its Annual Report on Form 10-K for the fiscal year ended December 29, 2013, filed with the SEC (the “2013 Form 10-K”). The balance sheet amounts at December 29, 2013 in this report were derived from the Company’s audited 2013 consolidated financial statements included in the 2013 Form 10-K. The condensed consolidated financial statements reflect all adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods indicated. The preparation of financial statements in conformity with U.S. Generally Accepted Accounting Principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The results of operations for the three and nine months ended September 28, 2014 and September 29, 2013, respectively, are not necessarily indicative of the results for the entire fiscal year or any future period. The Company has evaluated subsequent events from September 28, 2014 through the date of the issuance of these condensed consolidated financial statements and has determined that no material subsequent events have occurred that would affect the information presented in these condensed consolidated financial statements or would require additional disclosure.
	Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s condensed consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
	In April 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under this new guidance, only disposals of components of an entity that represent strategic shifts that have, or will have, a major effect on an entity's operations and financial results will be presented as discontinued operations. The standard also requires new disclosures related to individually significant disposals that do not meet the definition of a discontinued operation. The provisions of this guidance are effective for interim and annual periods beginning after December 15, 2014. The Company is evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company’s condensed consolidated financial position, results of operations and cash flows.
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. Under this new guidance, an entity should use a five-step process to recognize revenue, which depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The provisions of this guidance are effective for interim and annual periods beginning after December 15, 2016. The Company is evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company’s condensed consolidated financial position, results of operations and cash flows.

Business_Combinations

Business Combinations	9 Months Ended
	Sep. 28, 2014
Business Combinations [Abstract]	'
Business Combinations	'
	Business Combinations
	Acquisitions in fiscal year 2014
	During the first nine months of fiscal year 2014, the Company completed an acquisition for total consideration of $1.5 million in cash, and $4.3 million of assumed debt. In addition, during October 2014 the Company completed an acquisition for total consideration of $16.7 million. The excess of the purchase prices over the fair value of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and is allocated to goodwill, none of which is tax deductible. The Company reported, or expects to report, the operations for these acquisitions within the results of the Company's operations from the acquisition dates. As of September 28, 2014, the purchase accounting allocation related to the acquisition completed during the first nine months of fiscal year 2014 was preliminary.
	Acquisitions in fiscal year 2013
	During fiscal year 2013, the Company completed the acquisition of four businesses for total consideration of $11.4 million, in cash. During the first nine months of fiscal year 2014, the Company paid $0.4 million in additional deferred consideration for one of these acquisitions. As of the closing date of that acquisition, the Company potentially had to pay additional contingent consideration for the business of up to $2.2 million, which at closing had an estimated fair value of $1.1 million. The excess of the purchase prices over the fair values of each of the acquired businesses' net assets represents cost and revenue synergies specific to the Company, as well as non-capitalizable intangible assets, such as the employee workforce acquired, and have been allocated to goodwill, none of which is tax deductible. The Company reported the operations for these acquisitions within the results of the Company's operations from the acquisition dates. As of September 28, 2014, the purchase accounting allocations related to these acquisitions were preliminary, with the exception of those acquisitions completed during the first nine months of fiscal year 2013.
	The preliminary allocations of the purchase prices for these acquisitions were based upon initial valuations. The Company's estimates and assumptions underlying the initial valuations are subject to the collection of information necessary to complete the Company's valuations within the measurement periods, which are up to one year from the acquisition dates. The primary areas of the preliminary purchase price allocations that are not yet finalized relate to the fair value of certain tangible and intangible assets acquired and liabilities assumed, assets and liabilities related to income taxes and related valuation allowances, and residual goodwill. The Company expects to continue to obtain information to assist in determining the fair values of the net assets acquired at the acquisition dates during the measurement periods. During the measurement periods, the Company will adjust assets or liabilities if new information is obtained about facts and circumstances that existed as of the acquisition dates that, if known, would have resulted in the recognition of those assets and liabilities as of those dates. Adjustments to the preliminary allocations of the purchase prices during the measurement periods require the revision of comparative prior period financial information when reissued in subsequent financial statements. The effect of adjustments to the allocations of the purchase prices made during the measurement periods would be as if the adjustments had been completed on the acquisition dates. The effects of any such adjustments, if material, may cause changes in depreciation, amortization, or other income or expense recognized in prior periods. All changes that do not qualify as adjustments made during the measurement periods are included in current period earnings.
	Allocations of the purchase price for acquisitions are based on estimates of the fair value of the net assets acquired and are subject to adjustment upon finalization of the purchase price allocations. The accounting for business combinations requires estimates and judgments as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair values for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period.
	The Company may have to pay contingent consideration, related to all acquisitions with open contingency periods, of up to $26.4 million as of September 28, 2014. As of September 28, 2014, the Company has recorded contingent consideration obligations relating to its acquisitions of Haoyuan Biotech Co. and Tetra Teknolojik Sistemler Limited Sirketi, with an estimated fair value of $1.3 million. The earnout period for each of these acquisitions does not exceed three years from the respective acquisition date. If the actual results differ from the estimates and judgments used in these fair values, the amounts recorded in the condensed consolidated financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of definite-lived intangible assets or the recognition of additional consideration which would be expensed.
	Total transaction costs related to acquisition activities for the three and nine months ended September 28, 2014 were $0.04 million and $0.2 million, respectively. Total transaction costs related to acquisition activities for the three and nine months ended September 29, 2013 were zero and $0.1 million, respectively. These transaction costs were expensed as incurred and recorded in selling, general and administrative expenses in the Company's condensed consolidated statements of operations.

Discontinued_Operations

Discontinued Operations	9 Months Ended
	Sep. 28, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
Discontinued Operations	'
	Discontinued Operations
	As part of the Company’s continuing efforts to focus on higher growth opportunities, the Company has discontinued certain businesses. The Company has accounted for these businesses as discontinued operations and, accordingly, has presented the results of operations and related cash flows as discontinued operations for all periods presented. Any remaining assets and liabilities of these businesses have been presented separately, and are reflected within the assets and liabilities from discontinued operations in the accompanying condensed consolidated balance sheets as of September 28, 2014 and December 29, 2013.
	The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Loss on disposition of microarray-based diagnostic testing laboratory	$	—		$	—		$	(257	)	$	—
	Gain on disposition of Photoflash business	—			—			—			493
	Loss on disposition of other discontinued operations	(7		)	(64		)	(124		)	(36		)
	(Loss) gain on disposition of discontinued operations, before income taxes	$	(7	)	$	(64	)	$	(381	)	$	457
	In May 2014, the Company’s management approved the shutdown of its microarray-based diagnostic testing laboratory in the United States, which has been reported within the Human Health segment. The Company determined that, with the lack of adequate reimbursement from health care payers, the microarray-based diagnostic testing laboratory in the United States would need significant investment in its operations to reduce costs in order to effectively compete in the market. The shutdown of the microarray-based diagnostic testing laboratory in the United States resulted in a $0.3 million pre-tax loss related to the disposal of fixed assets and inventory during the nine months ended September 28, 2014.
	In June 2010, the Company sold its Photoflash business, which was included in the Company's Environmental Health segment. During the nine months ended September 29, 2013, the Company recognized a pre-tax gain of $0.5 million for contingent consideration related to this sale. This gain was recognized as a gain on disposition of discontinued operations.
	During the first nine months of both fiscal years 2014 and 2013, the Company settled various commitments related to the divestiture of other discontinued operations. The Company recognized pre-tax losses in the first nine months of both fiscal years 2014 and 2013. These losses were recognized as a loss on disposition of discontinued operations.
	Summary pre-tax operating results of the discontinued operations for the periods prior to disposition, which included a $1.0 million pre-tax charge related to workforce reductions in the microarray-based diagnostic testing laboratory in the United States during the second quarter of fiscal year 2014, were as follows:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Sales	$	—		$	2,177		$	960		$	7,236
	Costs and expenses	1,091			2,935			5,165			9,339
	Loss from discontinued operations before income taxes	$	(1,091	)	$	(758	)	$	(4,205	)	$	(2,103	)
	The Company recorded a tax benefit of $0.5 million and a tax benefit of $1.7 million on discontinued operations and dispositions for the three and nine months ended September 28, 2014, respectively. The Company recorded a tax benefit of $0.3 million and a tax benefit of $1.2 million on discontinued operations and dispositions for the three and nine months ended September 29, 2013, respectively.

Restructuring_and_Lease_Charge

Restructuring and Lease Charges, Net	9 Months Ended
	Sep. 28, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring and Lease Charges, Net	'
	Restructuring and Contract Termination Charges, Net
	The Company has undertaken a series of restructuring actions related to the impact of acquisitions and divestitures, alignment with the Company’s growth strategy, the integration of its business units and productivity initiatives. The current portion of restructuring and contract termination charges is recorded in accrued restructuring and contract termination charges and the long-term portion of restructuring and contract termination charges is recorded in long-term liabilities. The activities associated with these plans have been reported as restructuring and contract termination charges, net, and are included as a component of operating expenses from continuing operations.
	A description of the restructuring plans and the activity recorded for the nine months ended September 28, 2014 is listed below. Details of the plans initiated in previous years, particularly those listed under “Previous Restructuring and Integration Plans,” are discussed more fully in Note 4 to the audited consolidated financial statements in the 2013 Form 10-K.
	The restructuring plan for the third quarter of fiscal year 2014 was principally intended to realign resources to emphasize growth initiatives. The restructuring plans for the first and second quarters of fiscal year 2014 and the first quarter of fiscal year 2013 were principally intended to focus resources on higher growth end markets. The restructuring plans for the fourth and third quarters of fiscal year 2013 were principally intended to shift certain of the Company's research and development resources into a newly opened Center for Innovation. The restructuring plan for the second quarter of fiscal year 2013 was principally intended to shift certain of the Company's operations into a newly established shared service center as well as realign operations, research and development resources and production resources as a result of previous acquisitions.
	A description of the restructuring plans and the activity recorded are as follows:
	Q3 2014 Restructuring Plan
	During the third quarter of fiscal year 2014, the Company’s management approved a plan principally intended to realign resources to emphasize growth initiatives (the “Q3 2014 Plan”). As a result of the Q3 2014 Plan, the Company recognized pre-tax restructuring charges of $6.9 million in the Human Health segment and $6.2 million in the Environmental Health segment related to workforce reductions from reorganization activities. As part of the Q3 2014 Plan, the Company reduced headcount by 152 employees. All employees were notified of termination, or in some cases the intention to terminate, under the Q3 2014 Plan by September 28, 2014.
	The following table summarizes the Q3 2014 Plan activity for the nine months ended September 28, 2014:
		Severance
		(In thousands)
	Provision	$	13,051
	Amounts paid and foreign currency translation	(694		)
	Balance at September 28, 2014	$	12,357
	The Company anticipates that the remaining severance payments of $12.4 million for workforce reductions will be substantially completed by the end of the third quarter of fiscal year 2015.
	Q2 2014 Restructuring Plan
	During the second quarter of fiscal year 2014, the Company’s management approved a plan principally intended to focus resources on higher growth end markets (the “Q2 2014 Plan”). As a result of the Q2 2014 Plan, the Company recognized pre-tax restructuring charges of $0.5 million in the Human Health segment and $0.3 million in the Environmental Health segment related to workforce reductions from reorganization activities. As part of the Q2 2014 Plan, the Company reduced headcount by 22 employees. All employees were notified of termination under the Q2 2014 Plan by June 29, 2014.
	The following table summarizes the Q2 2014 Plan activity for the nine months ended September 28, 2014:
		Severance
		(In thousands)
	Provision	$	735
	Amounts paid and foreign currency translation	(410		)
	Balance at September 28, 2014	$	325
	The Company anticipates that the remaining severance payments of $0.3 million for workforce reductions will be substantially completed by the end of the second quarter of fiscal year 2015.
	Q1 2014 Restructuring Plan
	During the first quarter of fiscal year 2014, the Company’s management approved a plan principally intended to focus resources on higher growth end markets (the “Q1 2014 Plan”). As a result of the Q1 2014 Plan, the Company recognized pre-tax restructuring charges of $0.4 million in the Human Health segment and $0.2 million in the Environmental Health segment related to workforce reductions from reorganization activities. As part of the Q1 2014 Plan, the Company reduced headcount by 17 employees. All employees were notified of termination under the Q1 2014 Plan by March 30, 2014.
	The following table summarizes the Q1 2014 Plan activity for the nine months ended September 28, 2014:
		Severance
		(In thousands)
	Provision	$	567
	Amounts paid and foreign currency translation	(395		)
	Balance at September 28, 2014	$	172
	The Company anticipates that the remaining severance payments of $0.2 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014.
	Q4 2013 Restructuring Plan
	During the fourth quarter of fiscal year 2013, the Company’s management approved a plan principally intended to shift certain of the Company's research and development resources into a newly opened Center for Innovation (the “Q4 2013 Plan”). As a result of the Q4 2013 Plan, the Company recognized an $8.2 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space and recognized a $3.0 million pre-tax restructuring charge in the Environmental Health segment related to a workforce reduction from reorganization activities. As part of the Q4 2013 Plan, the Company reduced headcount by 73 employees. All employees were notified of termination under the Q4 2013 Plan by December 29, 2013.
	The following table summarizes the Q4 2013 Plan activity for the nine months ended September 28, 2014:
		Severance			Closure of			Total
					Excess Facility
					Space
		(In thousands)
	Balance at December 29, 2013	$	1,987		$	6,854		$	8,841
	Amounts paid and foreign currency translation	(1,506		)	(1,501		)	(3,007		)
	Balance at September 28, 2014	$	481		$	5,353		$	5,834
	The Company anticipates that the remaining severance payments of $0.5 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014. The Company also anticipates that the remaining payments of $5.4 million, net of estimated sublease income, for the closure of the excess facility space will be paid through fiscal year 2019, in accordance with the terms of the applicable leases.
	Q3 2013 Restructuring Plan
	During the third quarter of fiscal year 2013, the Company’s management approved a plan principally intended to shift certain of the Company's research and development resources into a newly opened Center for Innovation (the “Q3 2013 Plan”). As a result of the Q3 2013 Plan, the Company recognized a $0.5 million pre-tax restructuring charge in the Human Health segment related to a workforce reduction from reorganization activities and the closure of excess facility space. As part of the Q3 2013 Plan, the Company reduced headcount by 29 employees. All employees were notified of termination under the Q3 2013 Plan by September 29, 2013.
	The following table summarizes the Q3 2013 Plan activity for the nine months ended September 28, 2014:
		Severance
		(In thousands)
	Balance at December 29, 2013	$	137
	Amounts paid and foreign currency translation	(137		)
	Balance at September 28, 2014	$	—
	There are no severance payments remaining to be made under the Q3 2013 Plan.
	Q2 2013 Restructuring Plan
	During the second quarter of fiscal year 2013, the Company’s management approved a plan principally intended to shift certain of the Company's operations into a newly established shared service center as well as realign operations, research and development resources, and production resources as a result of previous acquisitions (the “Q2 2013 Plan”). As a result of the Q2 2013 Plan, the Company initially recognized pre-tax restructuring charges of $9.9 million in the Human Health segment and $8.8 million in the Environmental Health segment related to workforce reductions from reorganization activities and the closures of excess facility space. Subsequent to the initial charge, during fiscal year 2013, the Company recorded an additional $0.6 million pre-tax restructuring charge in the Human Health segment for services that were provided for one-time benefits in which the employee was required to render service beyond the legal notification period. During the nine months ended September 28, 2014, the Company recorded additional pre-tax restructuring charges of $0.1 million in each of the Human Health and Environmental Health segments due to higher than expected costs associated with the closure of the excess facility space. As part of the Q2 2013 Plan, the Company reduced headcount by 264 employees. All employees were notified of termination under the Q2 2013 Plan by June 30, 2013.
	The following table summarizes the Q2 2013 Plan activity for the nine months ended September 28, 2014:
		Severance			Closure of			Total
					Excess Facility
					Space
		(In thousands)
	Balance at December 29, 2013	$	12,750		$	—		$	12,750
	Change in estimates	—			184			184
	Amounts paid and foreign currency translation	(9,610		)	(184		)	(9,794		)
	Balance at September 28, 2014	$	3,140		$	—		$	3,140
The Company anticipates that the remaining severance payments of $3.1 million for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014, as local law requires some severance to be paid in monthly installments through the fourth quarter of fiscal year 2014. The closure of the excess facility space will not require any additional payments.
Q1 2013 Restructuring Plan
During the first quarter of fiscal year 2013, the Company’s management approved a plan principally intended to focus resources on higher growth end markets (the “Q1 2013 Plan”). As a result of the Q1 2013 Plan, the Company recognized pre-tax restructuring charges of $2.3 million in the Human Health segment and $0.2 million in the Environmental Health segment related to workforce reductions from reorganization activities. During the nine months ended September 28, 2014, the Company recorded a pre-tax restructuring reversal of $0.2 million in the Human Health segment due to lower than expected costs associated with the remaining severance payments. As part of the Q1 2013 Plan, the Company reduced headcount by 62 employees. All employees were notified of termination under the Q1 2013 Plan by March 31, 2013.
The following table summarizes the Q1 2013 Plan activity for the nine months ended September 28, 2014:
	Severance
	(In thousands)
Balance at December 29, 2013	$	208
Change in estimates	(208		)
Balance at September 28, 2014	$	—
There are no severance payments remaining to be made under the Q1 2013 Plan.
Previous Restructuring and Integration Plans
The principal actions of the restructuring and integration plans from fiscal year 2001 through fiscal year 2012 were workforce reductions and the closure of excess facility space related to the integration of the Company’s businesses in order to realign operations, reduce costs, achieve operational efficiencies and shift resources into geographic regions and end markets that are more consistent with the Company’s growth strategy. During the nine months ended September 28, 2014, the Company paid $4.5 million related to these plans and recognized pre-tax restructuring reversals of $0.8 million in the Human Health Segment and $1.1 million in the Environmental Health Segment related to lower than expected costs associated with workforce reductions. As of September 28, 2014, the Company had $6.9 million of remaining liabilities associated with these restructuring and integration plans, primarily for residual lease obligations related to closed facilities and remaining severance payments for workforce reductions in both the Human Health and Environmental Health segments. The Company expects to make payments for these leases, the terms of which vary in length, through fiscal year 2022. The Company anticipates the remaining severance payments for workforce reductions will be substantially completed by the end of the fourth quarter of fiscal year 2014, as local law requires some severance to be paid in monthly installments through the fourth quarter of fiscal year 2014.
Contract Termination Charges
The Company has terminated various contractual commitments in connection with certain disposal activities and has recorded charges, to the extent applicable, for the costs of terminating these contracts before the end of their terms and the costs that will continue to be incurred for the remaining terms without economic benefit to the Company. The Company recorded an additional pre-tax charge of $1.5 million, primarily as a result of terminating various contractual commitments in the Environmental Health segment, and the Company made payments for these obligations of $1.5 million in the first nine months of fiscal year 2014. The remaining balance of these accruals as of September 28, 2014 was $0.4 million.

Interest_and_Other_Expense_Inc

Interest and Other Expense (Income), Net	9 Months Ended
	Sep. 28, 2014
Other Income and Expenses [Abstract]	'
Interest and Other Expense (Income), Net	'
	Interest and Other Expense, Net
	Interest and other expense, net, consisted of the following:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Interest income	$	(130	)	$	(119	)	$	(375	)	$	(288	)
	Interest expense	8,909			11,704			27,207			35,310
	Other expense, net	2,187			755			4,387			2,223
	Total interest and other expense, net	$	10,966		$	12,340		$	31,219		$	37,245

Inventories_Net

Inventories, Net	9 Months Ended
	Sep. 28, 2014
Inventory Disclosure [Abstract]	'
Inventories, Net	'
	Inventories, Net
	Inventories as of September 28, 2014 and December 29, 2013 consisted of the following:
		September 28,		December 29,
		2014		2013
		(In thousands)
	Raw materials	$	98,737	$	92,713
	Work in progress	17,450		15,505
	Finished goods	165,430		152,640
	Total inventories, net	$	281,617	$	260,858

Income_Taxes

Income Taxes	9 Months Ended
	Sep. 28, 2014
Income Tax Disclosure [Abstract]	'
Income Taxes	'
	Income Taxes
	The Company regularly reviews its tax positions in each significant taxing jurisdiction in the process of evaluating its unrecognized tax benefits. The Company makes adjustments to its unrecognized tax benefits when: (i) facts and circumstances regarding a tax position change, causing a change in management’s judgment regarding that tax position; (ii) a tax position is effectively settled with a tax authority at a differing amount; and/or (iii) the statute of limitations expires regarding a tax position.
	At September 28, 2014, the Company had gross tax effected unrecognized tax benefits of $32.1 million, of which $28.3 million, if recognized, would affect the continuing operations effective tax rate. The remaining amount, if recognized, would affect discontinued operations.
	The Company believes that it is reasonably possible that approximately $3.0 million of its uncertain tax positions at September 28, 2014, including accrued interest and penalties, and net of tax benefits, may be resolved over the next twelve months as a result of lapses in applicable statutes of limitations and potential settlements. Various tax years after 2006 remain open to examination by certain jurisdictions in which the Company has significant business operations, such as China, Finland, Germany, Italy, Netherlands, Singapore, the United Kingdom and the United States. The tax years under examination vary by jurisdiction.
	During the first nine months of fiscal years 2014 and 2013, the Company recorded net discrete income tax benefits of $5.8 million and $15.6 million, respectively, primarily for reversals of uncertain tax position reserves and resolution of other tax matters. The $15.6 million discrete income tax benefits for the nine months ended September 29, 2013 included $9.4 million of reversals as a result of lapses in statutes of limitation during the first quarter of fiscal year 2013.

Debt

Debt	9 Months Ended
	Sep. 28, 2014
Debt Disclosure [Abstract]	'
Debt	'
	Debt
	Senior Unsecured Revolving Credit Facility. On January 8, 2014, the Company refinanced its debt held under a previous senior unsecured revolving credit facility and entered into a new senior unsecured revolving credit facility. The new senior unsecured revolving credit facility provides for $700.0 million of revolving loans and has an initial maturity of January 8, 2019. As of September 28, 2014, undrawn letters of credit in the aggregate amount of $12.2 million were treated as issued and outstanding under the new senior unsecured revolving credit facility. As of September 28, 2014, the Company had $368.8 million available for additional borrowing under the new facility. The Company uses the senior unsecured revolving credit facility for general corporate purposes, which may include working capital, refinancing existing indebtedness, capital expenditures, share repurchases, acquisitions and strategic alliances. The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing, plus a margin. The base rate is the higher of (i) the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii) the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%. At September 28, 2014, borrowings under the senior unsecured revolving credit facility were accruing interest based on the Eurocurrency rate. The Eurocurrency margin as of September 28, 2014 was 108 basis points. The weighted average Eurocurrency interest rate as of September 28, 2014 was 0.18%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.26%. At September 28, 2014, the Company had $319.0 million of borrowings in U.S. Dollars outstanding under the senior unsecured revolving credit facility. The credit agreement for the facility contains affirmative, negative and financial covenants and events of default similar to those contained in the Company's credit agreement for its previous facility. The financial covenants in the Company's senior unsecured revolving credit facility include a debt-to-capital ratio, and two contingent covenants, a maximum consolidated leverage ratio and a minimum consolidated interest coverage ratio, applicable if the Company's credit rating is downgraded below investment grade. During the nine months ended September 28, 2014, the Company capitalized $1.8 million of debt financing costs for the refinancing of debt held under its previous senior unsecured revolving credit facility. These debt financing costs are being amortized into interest and other expense, net, on a straight-line basis, over the term of the new senior unsecured revolving credit facility.
	The Company's previous senior unsecured revolving credit facility provided for $700.0 million of revolving loans and had an initial maturity of December 16, 2016. At December 29, 2013, the Company had $397.0 million of borrowings in U.S. Dollars outstanding under the previous senior unsecured revolving credit facility. The credit agreement for the previous facility contained affirmative, negative and financial covenants and events of default similar to those contained in the Company's new credit facility.
	5% Senior Unsecured Notes due in 2021. On October 25, 2011, the Company issued $500.0 million aggregate principal amount of senior unsecured notes due in 2021 (the “2021 Notes”) in a registered public offering and received $496.9 million of net proceeds from the issuance. The 2021 Notes were issued at 99.372% of the principal amount, which resulted in a discount of $3.1 million. As of September 28, 2014, the 2021 Notes had an aggregate carrying value of $497.6 million, net of $2.4 million of unamortized original issue discount. As of December 29, 2013, the 2021 Notes had an aggregate carrying value of $497.4 million, net of $2.6 million of unamortized original issue discount. The 2021 Notes mature in November 2021 and bear interest at an annual rate of 5%. Interest on the 2021 Notes is payable semi-annually on May 15th and November 15th each year. Prior to August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes in whole or in part, at its option, at a redemption price equal to the greater of (i) 100% of the principal amount of the 2021 Notes to be redeemed, plus accrued and unpaid interest, or (ii) the sum of the present values of the remaining scheduled payments of principal and interest in respect to the 2021 Notes being redeemed, discounted on a semi-annual basis, at the Treasury Rate plus 45 basis points, plus accrued and unpaid interest. At any time on or after August 15, 2021 (three months prior to their maturity date), the Company may redeem the 2021 Notes, at its option, at a redemption price equal to 100% of the principal amount of the 2021 Notes to be redeemed plus accrued and unpaid interest. Upon a change of control (as defined in the indenture governing the 2021 Notes ) and a contemporaneous downgrade of the 2021 Notes below investment grade, each holder of 2021 Notes will have the right to require the Company to repurchase such holder's 2021 Notes for 101% of their principal amount, plus accrued and unpaid interest.
	Financing Lease Obligations. In September 2012, the Company entered into agreements with the lessors of certain buildings that the Company is currently occupying and leasing to expand those buildings. The Company provided a portion of the funds needed for the construction of the additions to the buildings, which resulted in the Company being considered the owner of the buildings during the construction period. At the end of the construction period, the Company was not reimbursed by the lessors for all of the construction costs. The Company is therefore deemed to have continuing involvement and the leases qualify as financing leases under sale-leaseback accounting guidance, representing debt obligations for the Company and non-cash investing and financing activities. As a result, the Company capitalized $29.3 million in property and equipment, net, representing the fair value of the buildings with a corresponding increase to debt. The Company has also capitalized $11.5 million in additional construction costs necessary to complete the renovations to the buildings, which were funded by the lessors, with a corresponding increase to debt. At September 28, 2014, the Company had $39.5 million recorded for these financing lease obligations, of which $1.1 million was recorded as short-term debt and $38.5 million was recorded as long-term debt. At December 29, 2013, the Company had $40.3 million recorded for these financing lease obligations, of which $2.6 million was recorded as short-term debt and $37.7 million was recorded as long-term debt. The buildings are being depreciated on a straight-line basis over the terms of the leases to their estimated residual values, which will equal the remaining financing obligation at the end of the lease term. At the end of the lease term, the remaining balances in property, plant and equipment, net and debt will be reversed against each other.
	Other Obligations. At September 28, 2014, the Company had $3.6 million of borrowings under other obligation arrangements, of which $0.1 million was recorded as short-term debt and $3.5 million was recorded as long-term debt. At December 29, 2013, the Company had no borrowings under other obligation arrangements.

Earnings_Per_Share

Earnings Per Share	9 Months Ended
	Sep. 28, 2014
Earnings Per Share [Abstract]	'
Earnings Per Share	'
	Earnings Per Share
	Basic earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding during the period less restricted unvested shares. Diluted earnings per share was computed by dividing net income by the weighted-average number of common shares outstanding plus all potentially dilutive common stock equivalents, primarily shares issuable upon the exercise of stock options using the treasury stock method. The following table reconciles the number of shares utilized in the earnings per share calculations:
		Three Months Ended		Nine Months Ended
		September 28,	September 29,	September 28,	September 29,
		2014	2013	2014	2013
		(In thousands)
	Number of common shares—basic	112,646	111,827	112,662	112,285
	Effect of dilutive securities:
	Stock options	870	997	964	987
	Restricted stock awards	243	291	210	244
	Number of common shares—diluted	113,759	113,115	113,836	113,516
	Number of potentially dilutive securities excluded from calculation due to antidilutive impact	482	465	480	493
	Antidilutive securities include outstanding stock options with exercise prices and average unrecognized compensation cost in excess of the average fair market value of common stock for the related period. Antidilutive options were excluded from the calculation of diluted net income per share and could become dilutive in the future.

Industry_Segment_Information

Industry Segment Information	9 Months Ended
	Sep. 28, 2014
Segment Reporting [Abstract]	'
Industry Segment Information	'
	Industry Segment Information
	The Company discloses information about its operating segments based on the way that management organizes the segments within the Company for making operating decisions and assessing financial performance. The Company evaluates the performance of its operating segments based on revenue and operating income. Intersegment revenue and transfers are not significant. The Company’s management reviews the results of the Company’s operations by the Human Health and Environmental Health operating segments. The accounting policies of the operating segments are the same as those described in Note 1 to the audited consolidated financial statements in the 2013 Form 10-K. The principal products and services of the Company's two operating segments are:
	•	Human Health.    Develops diagnostics, tools and applications to help detect diseases earlier and more accurately and to accelerate the discovery and development of critical new therapies. The Human Health segment serves both the diagnostics and research markets.
	•	Environmental Health.    Provides products, services and solutions to facilitate the creation of safer food and consumer products, more secure surroundings and efficient energy resources. The Environmental Health segment serves the environmental, industrial and laboratory services markets.
	The Company has included the expenses for its corporate headquarters, such as legal, tax, audit, human resources, information technology, and other management and compliance costs, as well as the activity related to the mark-to-market adjustment on postretirement benefit plans, as “Corporate” below. The Company has a process to allocate and recharge expenses to the reportable segments when these costs are administered or paid by the corporate headquarters based on the extent to which the segment benefited from the expenses. These amounts have been calculated in a consistent manner and are included in the Company’s calculations of segment results to internally plan and assess the performance of each segment for all purposes, including determining the compensation of the business leaders for each of the Company’s operating segments.
	Revenue and operating income (loss) by operating segment, excluding discontinued operations, are shown in the table below:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Human Health
	Product revenue(1)	$	237,312		$	227,167		$	721,449		$	682,164
	Service revenue	64,213			63,040			185,770			184,256
	Total revenue	301,525			290,207			907,219			866,420
	Operating income from continuing operations	45,033			44,659			141,737			101,100
	Environmental Health
	Product revenue	128,621			128,578			391,578			394,225
	Service revenue	111,903			103,315			330,032			305,071
	Total revenue	240,524			231,893			721,610			699,296
	Operating income from continuing operations(1)	21,596			21,896			73,967			61,922
	Corporate
	Operating loss from continuing operations(2) (3)	(7,853		)	(8,601		)	(35,529		)	(28,158		)
	Continuing Operations
	Product revenue	365,933			355,745			1,113,027			1,076,389
	Service revenue	176,116			166,355			515,802			489,327
	Total revenue	542,049			522,100			1,628,829			1,565,716
	Operating income from continuing operations	58,776			57,954			180,175			134,864
	Interest and other expense, net (see Note 5)	10,966			12,340			31,219			37,245
	Income from continuing operations before income taxes	$	47,810		$	45,614		$	148,956		$	97,619
	____________________________
	(1)	In the third quarter of fiscal year 2014, the Company settled litigation and entered into a fully paid license related to the Company's microfluidics technology licensing program. The Company has allocated the proceeds of this license between revenue and litigation settlement using the residual method and concluded that the litigation settlement had no value. The Company has no future performance obligations associated with this license. The Company recognized revenue of $7.5 million in cash from the license within the Human Health segment. Also within the Human Health segment, the Company recognized revenue of $2.6 million in other consideration resulting from concurrent modifications to an existing collaboration agreement.
	(2)	Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax gain of $0.1 million for each of the nine months ended September 28, 2014 and September 29, 2013. There were no expenses related to the mark-to-market adjustment on postretirement benefit plans for either the three months ended September 28, 2014 or September 29, 2013.
	(3)	In 2002, Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”) filed a complaint that alleged that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and in the third quarter of fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded during the second quarter of fiscal year 2014. In addition, $3.4 million of expenses were incurred and recorded in preparation for the trial during the six months ended June 29, 2014.

Stockholders_Equity

Stockholders' Equity	9 Months Ended
	Sep. 28, 2014
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity	'
	Stockholders’ Equity
	Comprehensive Income:
	The components of accumulated other comprehensive income consisted of the following:
		September 28,			December 29,
		2014			2013
		(In thousands)
	Foreign currency translation adjustments	$	46,687		$	76,283
	Unrecognized prior service costs, net of income taxes	1,429			1,429
	Unrealized net losses on securities, net of income taxes	(163		)	(121		)
	Accumulated other comprehensive income	$	47,953		$	77,591
	In December 2013, the Company redeemed all of its 6% senior unsecured notes due in 2015 and wrote-off the remaining unamortized derivative losses for previously settled cash flow hedges. During the nine months ended September 29, 2013, pre-tax losses of $1.5 million were reclassified from accumulated other comprehensive income into interest and other expense, net related to previously settled cash flow hedges. The Company recognized a tax benefit of $0.6 million related to these amounts reclassified out of accumulated other comprehensive income for the nine months ended September 29, 2013.
	Stock Repurchase Program:
	On October 24, 2012, the Company's Board of Directors ("the Board") authorized the Company to repurchase up to 6.0 million shares of common stock under a stock repurchase program (the "Repurchase Program"). The Repurchase Program expired on October 24, 2014. On October 23, 2014, the Board authorized the Company to repurchase up to 8.0 million shares of common stock under a new stock repurchase program (the "New Repurchase Program"). The New Repurchase Program will expire on October 23, 2016 unless terminated earlier by the Board, and may be suspended or discontinued at any time. During the nine months ended September 28, 2014, the Company repurchased 0.8 million shares of common stock in the open market at an aggregate cost of $34.8 million, including commissions, under the Repurchase Program. As of September 28, 2014, 1.7 million shares of the Company’s common stock remained available for repurchase from the 6.0 million shares authorized by the Board under the Repurchase Program. These shares ceased to be available for repurchase under the Repurchase Program upon its expiration on October 24, 2014.
	The Board has authorized the Company to repurchase shares of common stock to satisfy minimum statutory tax withholding obligations in connection with the vesting of restricted stock awards and restricted stock unit awards granted pursuant to the Company’s equity incentive plans and to satisfy obligations related to the exercise of stock options made pursuant to the Company's equity incentive plans. During the nine months ended September 28, 2014, the Company repurchased 97,774 shares of common stock for this purpose at an aggregate cost of $4.2 million. The repurchased shares have been reflected as additional authorized but unissued shares, with the payments reflected in common stock and capital in excess of par value.
	Dividends:
	The Board declared a regular quarterly cash dividend of $0.07 per share for each of the first three quarters of fiscal year 2014 and in each quarter of fiscal year 2013. At September 28, 2014, the Company has accrued $7.9 million for dividends declared on July 24, 2014 for the third quarter of fiscal year 2014, payable in November 2014. On October 23, 2014, the Company announced that the Board had declared a quarterly dividend of $0.07 per share for the fourth quarter of fiscal year 2014 that will be payable in February 2014. In the future, the Board may determine to reduce or eliminate the Company’s common stock dividend in order to fund investments for growth, repurchase shares or conserve capital resources.

Stock_Plans

Stock Plans	9 Months Ended
	Sep. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Stock Plans	'
	Stock Plans
	In addition to the Company's Employee Stock Purchase Plan, the Company utilizes one stock-based compensation plan, the 2009 Incentive Plan (the “2009 Plan”). Under the 2009 Plan, 10.0 million shares of the Company's common stock are authorized for stock option grants, restricted stock awards, performance units and stock grants as part of the Company’s compensation programs. In addition to shares of the Company’s common stock originally authorized for issuance under the 2009 Plan, the 2009 Plan includes shares of the Company’s common stock previously granted under the Amended and Restated 2001 Incentive Plan and the 2005 Incentive Plan that were canceled or forfeited without the shares being issued.
	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s condensed consolidated statements of operations for the three and nine months ended September 28, 2014 and September 29, 2013:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Cost of product and service revenue	$	386		$	337		$	1,056		$	958
	Research and development expenses	39			203			400			629
	Selling, general and administrative expenses	2,025			3,241			10,313			9,836
	Total stock-based compensation expense	$	2,450		$	3,781		$	11,769		$	11,423
	The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $0.8 million and $4.2 million for the three and nine months ended September 28, 2014, respectively. The total income tax benefit recognized in the condensed consolidated statements of operations for stock-based compensation was $1.2 million and $3.6 million for the three and nine months ended September 29, 2013, respectively. Stock-based compensation costs capitalized as part of inventory were $0.4 million and $0.3 million as of September 28, 2014 and September 29, 2013, respectively. The excess tax benefit recognized from stock compensation, classified as a financing cash activity, was zero for each of the nine months ended September 28, 2014 and September 29, 2013.
	Stock Options: The fair value of each option grant is estimated using the Black-Scholes option pricing model. The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows:
		Three and Nine Months Ended
		September 28,		September 29,
		2014		2013
	Risk-free interest rate	1.5	%	0.9	%
	Expected dividend yield	0.7	%	0.8	%
	Expected lives	5 years		5 years
	Expected stock volatility	30.9	%	38.5	%
	The following table summarizes stock option activity for the nine months ended September 28, 2014:
		Number		Weighted-			Weighted-Average		Total
		of		Average Exercise			Remaining		Intrinsic
		Shares		Price			Contractual Term		Value
		(In thousands)					(In years)		(In millions)
	Outstanding at December 29, 2013	3,494		$	23.34
	Granted	520		43.12
	Exercised	(889	)	23.55
	Canceled	(4	)	20.97
	Forfeited	(108	)	34.85
	Outstanding at September 28, 2014	3,013		$	26.28		3.6		$	58.2
	Exercisable at September 28, 2014	2,033		$	21.46		2.6		$	49.1
	Vested and expected to vest in the future	2,972		$	26.18		3.5		$	57.8
	The weighted-average per-share grant-date fair value of options granted during the three and nine months ended September 28, 2014 was $12.78 and $11.86, respectively. There were no options granted during the three months ended September 29, 2013. The weighted-average per-share grant-date fair value of options granted during the nine months ended September 29, 2013 was $10.82. The total intrinsic value of options exercised during the three and nine months ended September 28, 2014 was $1.9 million and $19.6 million, respectively. The total intrinsic value of options exercised during the three and nine months ended September 29, 2013 was $6.2 million and $10.3 million, respectively. Cash received from option exercises for the nine months ended September 28, 2014 and September 29, 2013 was $20.9 million and $15.3 million, respectively.
	The total compensation expense recognized related to the Company’s outstanding options was $1.0 million and $3.9 million for the three and nine months ended September 28, 2014, respectively, and $1.1 million and $3.2 million for the three and nine months ended September 29, 2013, respectively.
	There was $7.1 million of total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock options granted as of September 28, 2014. This cost is expected to be recognized over a weighted-average period of 1.9 years and will be adjusted for any future changes in estimated forfeitures.
	Restricted Stock Awards: The following table summarizes restricted stock award activity for the nine months ended September 28, 2014:
		Number of		Weighted-
		Shares		Average
				Grant-
				Date Fair
				Value
		(In thousands)
	Nonvested at December 29, 2013	649		$	29.24
	Granted	242		42.69
	Vested	(256	)	27.68
	Forfeited	(67	)	33.35
	Nonvested at September 28, 2014	568		$	35.2
	The weighted-average per-share grant-date fair value of restricted stock awards granted during the three and nine months ended September 28, 2014 was $45.42 and $42.69, respectively. The weighted-average per-share grant-date fair value of restricted stock awards granted during the three and nine months ended September 29, 2013 was $36.11 and $33.74, respectively. The fair value of restricted stock awards vested during the three and nine months ended September 28, 2014 was $0.1 million and $7.1 million, respectively. The fair value of restricted stock awards vested during the three and nine months ended September 29, 2013 was $0.4 million and $7.6 million, respectively. The total compensation expense recognized related to the Company’s outstanding restricted stock awards was $1.6 million and $5.5 million for the three and nine months ended September 28, 2014, respectively, and $1.7 million and $5.6 million for the three and nine months ended September 29, 2013, respectively.
	As of September 28, 2014, there was $11.7 million of total unrecognized compensation cost, net of forfeitures, related to nonvested restricted stock awards. That cost is expected to be recognized over a weighted-average period of 1.4 years.
	Performance Units: The Company granted 79,463 and 98,056 performance units during the nine months ended September 28, 2014 and September 29, 2013, respectively, as part of the Company’s executive incentive program. The weighted-average per-share grant-date fair value of performance units granted during the nine months ended September 28, 2014 and September 29, 2013 was $42.84 and $34.06, respectively. During the nine months ended September 28, 2014 and September 29, 2013, 19,667 and 28,515 performance units were forfeited, respectively. The total compensation expense recognized related to performance units was a reversal of expense of $0.2 million and an expense of $1.6 million for the three and nine months ended September 28, 2014, respectively, and expenses of $1.0 million and $1.9 million for the three and nine months ended September 29, 2013, respectively. As of September 28, 2014, there were 252,012 performance units outstanding and subject to forfeiture, with a corresponding liability of $4.2 million recorded in accrued expenses and other current liabilities.
	Stock Awards: The Company generally grants stock awards only to non-employee members of the Board. The Company granted 2,373 shares and 3,263 shares to each non-employee member of the Board during the nine months ended September 28, 2014 and September 29, 2013, respectively. The weighted-average per-share grant-date fair value of the stock awards granted during the nine months ended September 28, 2014 and September 29, 2013 was $42.14 and $30.65, respectively. The total compensation expense recognized related to these stock awards was $0.7 million for each of the nine months ended September 28, 2014 and September 29, 2013.
	Employee Stock Purchase Plan: During the nine months ended September 28, 2014, the Company issued 60,870 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $41.71 per share. During the nine months ended September 29, 2013, the Company issued 89,521 shares of common stock under the Company's Employee Stock Purchase Plan at a weighted-average price of $30.51 per share. At September 28, 2014, an aggregate of 1.0 million shares of the Company’s common stock remained available for sale to employees out of the 5.0 million shares authorized by shareholders for issuance under this plan.

Goodwill_and_Intangible_Assets

Goodwill and Intangible Assets, Net	9 Months Ended
	Sep. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets, Net	'
	Goodwill and Intangible Assets, Net
	The Company tests goodwill and non-amortizing intangible assets at least annually for possible impairment. Accordingly, the Company completes the annual testing of impairment for goodwill and non-amortizing intangible assets on the later of January 1 or the first day of each fiscal year. In addition to its annual test, the Company regularly evaluates whether events or circumstances have occurred that may indicate a potential impairment of goodwill or non-amortizing intangible assets.
	The process of testing goodwill for impairment involves the determination of the fair value of the applicable reporting units. The test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. The Company performed its annual impairment testing for its reporting units as of January 1, 2014, its annual impairment date for fiscal year 2014. The Company concluded based on the first step of the process that there was no goodwill impairment, and the fair value exceeded the carrying value by more than 90.0% for each reporting unit, with the exception of the life sciences and technology reporting unit where the fair value exceeded the carrying value by approximately 11.0%. The carrying value of the goodwill for the life sciences and technology reporting unit was $796.3 million, at the annual impairment date for fiscal year 2014. The long-term terminal growth rates for the Company’s reporting units ranged from 3.0% to 6.0% for the fiscal year 2014 impairment analysis. The range for the discount rates for the reporting units was 10.0% to 11.5%. Keeping all other variables constant, a 10.0% change in any one of the input assumptions for the various reporting units would still allow the Company to conclude, based on the first step of the process, that there was no impairment of goodwill.
	During the second quarter of 2014, the Company realigned its organization which resulted in a change in the composition of the Company's reporting units within the Human Health segment. The Company's informatics business was moved from the life sciences and technology reporting unit to its own reporting unit. As a result of the new alignment, the Company reallocated goodwill based on the relative fair value, determined using the income approach, of each of these businesses. During the third quarter of 2014, the Company finalized this analysis and the realignment resulted in $220.3 million of goodwill being reallocated from the life sciences and technology reporting unit to the informatics reporting unit. The Company concluded based on the first step of the process that there was no goodwill impairment for either the life sciences and technology reporting unit or the informatics reporting unit, and the fair value exceeded the carrying value by more than 20.0% for each of these reporting units.
	The Company has consistently employed the income approach to estimate the current fair value when testing for impairment of goodwill. A number of significant assumptions and estimates are involved in the application of the income approach to forecast operating cash flows, including markets and market share, sales volumes and prices, costs to produce, tax rates, capital spending, discount rate and working capital changes. Cash flow forecasts are based on approved business unit operating plans for the early years’ cash flows and historical relationships in later years. The income approach is sensitive to changes in long-term terminal growth rates and the discount rates. The long-term terminal growth rates are consistent with the Company’s historical long-term terminal growth rates, as the current economic trends are not expected to affect the long-term terminal growth rates of the Company.
	The Company has consistently employed the relief from royalty model to estimate the current fair value when testing for impairment of non-amortizing intangible assets. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, the Company evaluates the remaining useful lives of its non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful lives and accounted for in the same manner as other intangible assets that are subject to amortization. The Company performed its annual impairment testing as of January 1, 2014, and concluded that there was no impairment of non-amortizing intangible assets. An assessment of the recoverability of amortizing intangible assets takes place when events have occurred that may give rise to an impairment. No such events occurred during the first nine months of fiscal year 2014.
	The changes in the carrying amount of goodwill for the period ended September 28, 2014 from December 29, 2013 were as follows:
		Human			Environmental			Consolidated
		Health			Health
		(In thousands)
	Balance at December 29, 2013	$	1,648,332		$	494,788		$	2,143,120
	Foreign currency translation	(18,158		)	(5,443		)	(23,601		)
	Acquisitions and other	3,716			—			3,716
	Balance at September 28, 2014	$	1,633,890		$	489,345		$	2,123,235
	Identifiable intangible asset balances at September 28, 2014 and December 29, 2013 by category were as follows:
		September 28,			December 29,
		2014			2013
		(In thousands)
	Patents	$	39,971		$	39,591
	Less: Accumulated amortization	(26,560		)	(24,207		)
	Net patents	13,411			15,384
	Trade names and trademarks	34,846			35,809
	Less: Accumulated amortization	(17,803		)	(16,208		)
	Net trade names and trademarks	17,043			19,601
	Licenses	78,968			79,180
	Less: Accumulated amortization	(59,135		)	(52,930		)
	Net licenses	19,833			26,250
	Core technology	301,668			302,070
	Less: Accumulated amortization	(194,593		)	(169,326		)
	Net core technology	107,075			132,744
	Customer relationships	319,120			321,395
	Less: Accumulated amortization	(158,084		)	(132,833		)
	Net customer relationships	161,036			188,562
	IPR&D	10,388			9,483
	Less: Accumulated amortization	(2,904		)	(2,178		)
	Net IPR&D	7,484			7,305
	Net amortizable intangible assets	325,882			389,846
	Non-amortizing intangible assets:
	Trade names and trademarks	70,584			70,584
	Total	$	396,466		$	460,430
	Total amortization expense related to definite-lived intangible assets was $20.6 million and $61.9 million for the three and nine months ended September 28, 2014, respectively, and $22.8 million and $67.0 million for the three and nine months September 29, 2013, respectively. Estimated amortization expense related to definite-lived intangible assets for each of the next five years is $19.9 million for the remainder of fiscal year 2014, $69.2 million in fiscal year 2015, $60.2 million in fiscal year 2016, $50.7 million in fiscal year 2017, and $39.1 million in fiscal year 2018.

Warranty_Reserves

Warranty Reserves	9 Months Ended
	Sep. 28, 2014
Product Warranties Disclosures [Abstract]	'
Warranty Reserves	'
	Warranty Reserves
	The Company provides warranty protection for certain products usually for a period of one year beyond the date of sale. The majority of costs associated with warranty obligations include the replacement of parts and the time for service personnel to respond to repair and replacement requests. A warranty reserve is recorded based upon historical results, supplemented by management’s expectations of future costs. Warranty reserves are included in “Accrued expenses and other current liabilities” on the condensed consolidated balance sheets.
	A summary of warranty reserve activity for the three and nine months ended September 28, 2014 and September 29, 2013 is as follows:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Balance beginning of period	$	10,786		$	10,451		$	10,534		$	11,003
	Provision charged to income	4,187			4,160			12,596			12,673
	Payments	(4,154		)	(4,113		)	(12,509		)	(12,781		)
	Adjustments to previously provided warranties, net	(130		)	268			44			(54		)
	Foreign currency translation and acquisitions	(293		)	122			(269		)	47
	Balance end of period	$	10,396		$	10,888		$	10,396		$	10,888

Employee_Benefit_Plans

Employee Benefit Plans	9 Months Ended
	Sep. 28, 2014
Compensation and Retirement Disclosure [Abstract]	'
Employee Benefit Plans	'
	Employee Postretirement Benefit Plans
	The following table summarizes the components of net periodic benefit cost (credit) for the Company’s various defined benefit employee pension and postretirement plans for the three and nine months ended September 28, 2014 and September 29, 2013:
		Defined Benefit						Postretirement
		Pension Benefits						Medical Benefits
		Three Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Service cost	$	1,030		$	916		$	24		$	28
	Interest cost	5,914			5,312			39			36
	Expected return on plan assets	(6,277		)	(6,261		)	(241		)	(241		)
	Amortization of prior service costs	(72		)	(67		)	—			—
	Net periodic benefit cost (credit)	$	595		$	(100	)	$	(178	)	$	(177	)
		Defined Benefit						Postretirement
		Pension Benefits						Medical Benefits
		Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Service cost	$	3,094		$	2,757		$	72		$	85
	Interest cost	17,761			15,925			116			107
	Expected return on plan assets	(18,820		)	(18,778		)	(723		)	(723		)
	Amortization of prior service	(214		)	(201		)	—			—
	Net periodic benefit cost (credit)	$	1,821		$	(297	)	$	(535	)	$	(531	)
	During the first nine months of fiscal year 2014, the Company contributed $2.8 million, in the aggregate, to pension plans outside of the United States. During the first nine months of fiscal year 2013, the Company contributed $17.9 million, in the aggregate, to pension plans outside of the United States, including an additional contribution of $10.0 million to its defined benefit pension plan in the United Kingdom. During the first nine months of fiscal year 2013, the Company made contributions of $37.0 million for the 2012 plan year to its defined benefit pension plan in the United States.
	In the third quarter of fiscal year 2014, the Company notified employees of its intention to terminate their employment as part of the Q3 2014 restructuring plan. The removal of these participants will decrease the expected future service lives in excess of the curtailment limit for one of the Company's pension plans, resulting in a curtailment. The curtailment is expected to be a gain and will be measured and recorded when the notified employees separate from the Company. Employee separation is expected to begin during the fourth quarter of fiscal year 2014 and continue through the first half of fiscal year 2015.
	The Company recognizes actuarial gains and losses in operating results in the fourth quarter of the year in which the gains and losses occur, in accordance with the Company's accounting method for defined benefit pension plans and other postretirement benefits as described in Note 1 of the Company's audited consolidated financial statements and notes included in its 2013 Form 10-K. Such adjustments for gains and losses are primarily driven by events and circumstances beyond the Company's control, including changes in interest rates, the performance of the financial markets and mortality assumptions.

Derivatives_And_Hedging_Activi

Derivatives And Hedging Activities	9 Months Ended
	Sep. 28, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Derivatives and Hedging Activities	'
	Derivatives and Hedging Activities
	The Company uses derivative instruments as part of its risk management strategy only, and includes derivatives utilized as economic hedges that are not designated as hedging instruments. By nature, all financial instruments involve market and credit risks. The Company enters into derivative instruments with major investment grade financial institutions and has policies to monitor the credit risk of those counterparties. The Company does not enter into derivative contracts for trading or other speculative purposes, nor does the Company use leveraged financial instruments. Approximately 60% of the Company’s business is conducted outside of the United States, generally in foreign currencies. The fluctuations in foreign currency can increase the costs of financing, investing and operating the business. The intent of these economic hedges is to offset gains and losses that occur on the underlying exposures from these currencies, with gains and losses resulting from the forward currency contracts that hedge these exposures.
	In the ordinary course of business, the Company enters into foreign exchange contracts for periods consistent with its committed exposures to mitigate the effect of foreign currency movements on transactions denominated in foreign currencies. Transactions covered by hedge contracts include intercompany and third-party receivables and payables. The contracts are primarily in European and Asian currencies, have maturities that do not exceed 12 months, have no cash requirements until maturity, and are recorded at fair value on the Company’s condensed consolidated balance sheets. Unrealized gains and losses on the Company’s foreign currency contracts are recognized immediately in earnings for hedges designated as fair value and, for hedges designated as cash flow, the related unrealized gains or losses are deferred as a component of other comprehensive income in the accompanying condensed consolidated balance sheets. Deferred gains and losses are recognized in income in the period in which the underlying anticipated transaction occurs and impacts earnings.
	Principal hedged currencies include the British Pound, Euro, Japanese Yen and Singapore Dollar. The Company held forward foreign exchange contracts, designated as fair value hedges, with U.S. equivalent notional amounts totaling $127.2 million, $138.4 million and $110.0 million at September 28, 2014, December 29, 2013 and September 29, 2013, respectively, and the fair value of these foreign currency derivative contracts was insignificant. The gains and losses realized on foreign currency derivative contracts are not material. The duration of these contracts was generally 30 days or less during both fiscal years 2014 and 2013.
	In December 2012, the Company entered into forward foreign exchange contracts with settlement dates in fiscal year 2013 and combined Euro denominated notional amounts of €50.0 million, designated as cash flow hedges. During the nine months ended September 29, 2013, the Company settled these Euro denominated forward foreign exchange contracts. The derivative gains were recognized in income in the period in which the underlying hedged exposures occurred and impacted earnings, and were recorded in interest and other expense, net. Such amounts were not material for the three and nine months ended September 29, 2013.

Fair_Value_Measurements

Fair Value Measurements	9 Months Ended
	Sep. 28, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	Fair Value Measurements
	Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash equivalents, derivatives, marketable securities and accounts receivable. The Company believes it had no significant concentrations of credit risk as of September 28, 2014.
	The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during the nine months ended September 28, 2014. The Company’s financial assets and liabilities carried at fair value are primarily comprised of marketable securities, derivative contracts used to hedge the Company’s currency risk, and acquisition-related contingent consideration. The Company has not elected to measure any additional financial instruments or other items at fair value.
	Valuation Hierarchy: The following summarizes the three levels of inputs required to measure fair value. For Level 1 inputs, the Company utilizes quoted market prices as these instruments have active markets. For Level 2 inputs, the Company utilizes quoted market prices in markets that are not active, broker or dealer quotations, or utilizes alternative pricing sources with reasonable levels of price transparency. For Level 3 inputs, the Company utilizes unobservable inputs based on the best information available, including estimates by management primarily based on information provided by third-party fund managers, independent brokerage firms and insurance companies. A financial asset’s or liability’s classification within the hierarchy is determined based on the lowest level input that is significant to the fair value measurement. In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.
	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of September 28, 2014 and December 29, 2013 classified in one of the three classifications described above:
					Fair Value Measurements at September 28, 2014 Using:
		Total Carrying Value at September 28, 2014			Quoted Prices in			Significant Other			Significant
					Active Markets			Observable Inputs			Unobservable
					(Level 1)			(Level 2)			Inputs
											(Level 3)
		(In thousands)
	Marketable securities	$	1,391		$	1,391		$	—		$	—
	Foreign exchange derivative assets	220			—			220			—
	Foreign exchange derivative liabilities	(299		)	—			(299		)	—
	Contingent consideration	(1,286		)	—			—			(1,286		)
					Fair Value Measurements at December 29, 2013 Using:
		Total Carrying Value at December 29, 2013			Quoted Prices in			Significant Other			Significant
					Active Markets			Observable Inputs			Unobservable
					(Level 1)			(Level 2)			Inputs
											(Level 3)
		(In thousands)
	Marketable securities	$	1,319		$	1,319		$	—		$	—
	Foreign exchange derivative assets	293			—			293			—
	Foreign exchange derivative liabilities	(396		)	—			(396		)	—
	Contingent consideration	(4,926		)	—			—			(4,926		)
	Level 1 and Level 2 Valuation Techniques:    The Company’s Level 1 and Level 2 assets and liabilities are comprised of investments in equity and fixed-income securities as well as derivative contracts. For financial assets and liabilities that utilize Level 1 and Level 2 inputs, the Company utilizes both direct and indirect observable price quotes, including common stock price quotes, foreign exchange forward prices and bank price quotes. Below is a summary of valuation techniques for Level 1 and Level 2 financial assets and liabilities.
	Marketable securities:    Include equity and fixed-income securities measured at fair value using the quoted market prices in active markets at the reporting date.
	Foreign exchange derivative assets and liabilities:    Include foreign exchange derivative contracts that are valued using quoted forward foreign exchange prices at the reporting date. The Company’s foreign exchange derivative contracts are subject to master netting arrangements that allow the Company and its counterparties to net settle amounts owed to each other. Derivative assets and liabilities that can be net settled under these arrangements have been presented in the Company's consolidated balance sheet on a net basis and are recorded in other assets. As of both September 28, 2014 and December 29, 2013, none of the master netting arrangements involved collateral.
	Level 3 Valuation Techniques:    The Company’s Level 3 liabilities are comprised of contingent consideration related to acquisitions. For liabilities that utilize Level 3 inputs, the Company uses significant unobservable inputs. Below is a summary of valuation techniques for Level 3 liabilities.
	Contingent consideration:    The Company has classified its net liabilities for contingent consideration relating to its acquisitions within Level 3 of the fair value hierarchy because the fair value is determined using significant unobservable inputs, which included probability weighted cash flows. A description of the significant acquisitions is included within Note 2 to the Company's audited consolidated financial statements filed with the 2013 Form 10-K. Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period. Increases or decreases in the fair value of contingent consideration liabilities primarily result from changes in the estimated probabilities of achieving revenue thresholds or product development milestones during the earnout period. The Company may have to pay contingent consideration, related to all acquisitions with open contingency periods, of up to $26.4 million as of September 28, 2014. As of September 28, 2014, the Company has recorded contingent consideration obligations relating to its acquisitions of Haoyuan Biotech Co. and Tetra Teknolojik Sistemler Limited Sirketi, with an estimated fair value of $1.3 million at September 28, 2014. The earnout period for each of these acquisitions does not exceed three years from the respective acquisition date, and the remaining weighted average earnout period at September 28, 2014 was one year.
	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Balance beginning of period	$	(3,430	)	$	(3,715	)	$	(4,926	)	$	(3,017	)
	Additions	—			—			—			(1,100		)
	Amounts paid and foreign currency translation	2,137			31			2,065			95
	Change in fair value (included within selling, general and administrative expenses)	7			826			1,575			1,164
	Balance end of period	$	(1,286	)	$	(2,858	)	$	(1,286	)	$	(2,858	)
	The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses approximate fair value due to the short-term maturities of these assets and liabilities. If measured at fair value, cash and cash equivalents would be classified as Level 1.
	The Company’s new senior unsecured revolving credit facility, which provides for $700.0 million of revolving loans, had amounts outstanding, excluding letters of credit, of $319.0 million as of September 28, 2014. The Company’s previous senior unsecured revolving credit facility had amounts outstanding, excluding letters of credit, of $397.0 million as of December 29, 2013. The interest rate on the Company’s senior unsecured revolving credit facility is reset at least monthly to correspond to variable rates that reflect currently available terms and conditions for similar debt. The Company had no change in credit standing during the first nine months of fiscal year 2014. Consequently, the carrying value of the current year and prior year credit facilities approximate fair value and would be classified as Level 2.
	The Company's 2021 Notes, with a face value of $500.0 million, had an aggregate carrying value of $497.6 million, net of $2.4 million of unamortized original issue discount, and a fair value of $539.7 million as of September 28, 2014. The 2021 Notes had an aggregate carrying value of $497.4 million, net of $2.6 million of unamortized original issue discount, and a fair value of $513.0 million as of December 29, 2013. The fair value of the 2021 Notes is estimated using market quotes from brokers and is based on current rates offered for similar debt. The Company's financing lease obligations had an aggregate carrying value of $39.5 million and $40.3 million as of September 28, 2014 and December 29, 2013, respectively. The Company's other obligation arrangements had an aggregate carrying value of $3.6 million as of September 28, 2014. The carrying values of the Company's financing lease obligations and other obligations approximated their fair value as there has been minimal change in the Company's incremental borrowing rate. As of September 28, 2014, the 2021 Notes, financing lease obligations, and other obligation arrangements were classified as Level 2.
	As of September 28, 2014, there has not been any significant impact to the fair value of the Company’s derivative liabilities due to credit risk. Similarly, there has not been any significant adverse impact to the Company’s derivative assets based on the evaluation of its counterparties’ credit risks.

Leases

Leases	9 Months Ended
	Sep. 28, 2014
Leases [Abstract]	'
Leases of Lessee Disclosure [Text Block]	'
	Leases
	On August 22, 2013, the Company sold one of its facilities located in Boston, Massachusetts for net proceeds of $47.6 million. Simultaneously with the closing of the sale of the property, the Company entered into a lease agreement to lease back the property for its continued use. The lease has an initial term of 15 years and the Company has the right to extend the term of the lease for two additional periods of ten years each. The lease is accounted for as an operating lease and at the transaction date the Company had deferred $26.5 million of gains which are being amortized in operating expenses over the initial lease term of 15 years. During the nine months ended September 28, 2014, the Company amortized $1.3 million of deferred gains related to the lease. At September 28, 2014, $24.5 million of these deferred gains remained to be amortized, which were recorded in long-term liabilities. At December 29, 2013, $25.9 million of deferred gains remained to be amortized, which were recorded in long-term liabilities.

Contingencies

Contingencies	9 Months Ended
	Sep. 28, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Contingencies	'
	Contingencies
	The Company is conducting a number of environmental investigations and remedial actions at current and former locations of the Company and, along with other companies, has been named a potentially responsible party (“PRP”) for certain waste disposal sites. The Company accrues for environmental issues in the accounting period that the Company’s responsibility is established and when the cost can be reasonably estimated. The Company has accrued $12.3 million and $13.5 million as of September 28, 2014 and December 29, 2013, respectively, which represents management’s estimate of the cost of the remediation of known environmental matters, and does not include any potential liability for related personal injury or property damage claims. This amount is not discounted and does not reflect the recovery of any material amounts through insurance or indemnification arrangements. These cost estimates are subject to a number of variables, including the stage of the environmental investigations, the magnitude of the possible contamination, the nature of the potential remedies, possible joint and several liability, the time period over which remediation may occur, and the possible effects of changing laws and regulations. For sites where the Company has been named a PRP, management does not currently anticipate any additional liability to result from the inability of other significant named parties to contribute. The Company expects that the majority of such accrued amounts could be paid out over a period of up to ten years. As assessment and remediation activities progress at each individual site, these liabilities are reviewed and adjusted to reflect additional information as it becomes available. There have been no environmental problems to date that have had, or are expected to have, a material adverse effect on the Company’s condensed consolidated financial statements. While it is possible that a loss exceeding the amounts recorded in the condensed consolidated financial statements may be incurred, the potential exposure is not expected to be materially different from those amounts recorded.
	The Company is also subject to various other claims, legal proceedings and investigations covering a wide range of matters that arise in the ordinary course of its business activities. Although the Company has established accruals for potential losses that it believes are probable and reasonably estimable, in the opinion of the Company’s management, based on its review of the information available at this time, the total cost of resolving these other contingencies at September 28, 2014 should not have a material adverse effect on the Company’s condensed consolidated financial statements. However, each of these matters is subject to uncertainties, and it is possible that some of these matters may be resolved unfavorably to the Company.

Basis_of_Presentation_Policies

Basis of Presentation (Policies)	9 Months Ended
	Sep. 28, 2014
Accounting Policies [Abstract]	'
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Adopted and Issued Accounting Pronouncements: From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board and are adopted by the Company as of the specified effective dates. Unless otherwise discussed, such pronouncements did not have or will not have a significant impact on the Company’s condensed consolidated financial position, results of operations and cash flows or do not apply to the Company’s operations.
	In April 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity. Under this new guidance, only disposals of components of an entity that represent strategic shifts that have, or will have, a major effect on an entity's operations and financial results will be presented as discontinued operations. The standard also requires new disclosures related to individually significant disposals that do not meet the definition of a discontinued operation. The provisions of this guidance are effective for interim and annual periods beginning after December 15, 2014. The Company is evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company’s condensed consolidated financial position, results of operations and cash flows.
	In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers. Under this new guidance, an entity should use a five-step process to recognize revenue, which depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard also requires new disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The provisions of this guidance are effective for interim and annual periods beginning after December 15, 2016. The Company is evaluating the requirements of this guidance and has not yet determined the impact of its adoption on the Company’s condensed consolidated financial position, results of operations and cash flows.

Discontinued_Operations_Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 28, 2014
Discontinued Operations and Disposal Groups [Abstract]	'
Schedule of Gains and Losses on Disposition of Discontinued Operations [Table Text Block]	'
	The Company recorded the following pre-tax gains and losses, which have been reported as a net gain or loss on disposition of discontinued operations:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Loss on disposition of microarray-based diagnostic testing laboratory	$	—		$	—		$	(257	)	$	—
	Gain on disposition of Photoflash business	—			—			—			493
	Loss on disposition of other discontinued operations	(7		)	(64		)	(124		)	(36		)
	(Loss) gain on disposition of discontinued operations, before income taxes	$	(7	)	$	(64	)	$	(381	)	$	457
Schedule of Disposal Groups, Including Discontinued Operations, Income Statement, Balance Sheet and Additional Disclosures [Table Text Block]	'
	Summary pre-tax operating results of the discontinued operations for the periods prior to disposition, which included a $1.0 million pre-tax charge related to workforce reductions in the microarray-based diagnostic testing laboratory in the United States during the second quarter of fiscal year 2014, were as follows:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Sales	$	—		$	2,177		$	960		$	7,236
	Costs and expenses	1,091			2,935			5,165			9,339
	Loss from discontinued operations before income taxes	$	(1,091	)	$	(758	)	$	(4,205	)	$	(2,103	)

Restructuring_and_Lease_Charge1

Restructuring and Lease Charges, Net (Tables)	9 Months Ended
	Sep. 28, 2014
Q3 2014 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q3 2014 Plan activity for the nine months ended September 28, 2014:
		Severance
		(In thousands)
	Provision	$	13,051
	Amounts paid and foreign currency translation	(694		)
	Balance at September 28, 2014	$	12,357
Q2 2014 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q2 2014 Plan activity for the nine months ended September 28, 2014:
		Severance
		(In thousands)
	Provision	$	735
	Amounts paid and foreign currency translation	(410		)
	Balance at September 28, 2014	$	325
Q1 2014 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q1 2014 Plan activity for the nine months ended September 28, 2014:
		Severance
		(In thousands)
	Provision	$	567
	Amounts paid and foreign currency translation	(395		)
	Balance at September 28, 2014	$	172
Q4 2013 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q4 2013 Plan activity for the nine months ended September 28, 2014:
		Severance			Closure of			Total
					Excess Facility
					Space
		(In thousands)
	Balance at December 29, 2013	$	1,987		$	6,854		$	8,841
	Amounts paid and foreign currency translation	(1,506		)	(1,501		)	(3,007		)
	Balance at September 28, 2014	$	481		$	5,353		$	5,834
Q3 2013 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q3 2013 Plan activity for the nine months ended September 28, 2014:
		Severance
		(In thousands)
	Balance at December 29, 2013	$	137
	Amounts paid and foreign currency translation	(137		)
	Balance at September 28, 2014	$	—
Q2 2013 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q2 2013 Plan activity for the nine months ended September 28, 2014:
		Severance			Closure of			Total
					Excess Facility
					Space
		(In thousands)
	Balance at December 29, 2013	$	12,750		$	—		$	12,750
	Change in estimates	—			184			184
	Amounts paid and foreign currency translation	(9,610		)	(184		)	(9,794		)
	Balance at September 28, 2014	$	3,140		$	—		$	3,140
Q1 2013 Restructuring Plan [Member]	'
Restructuring Cost and Reserve [Line Items]	'
Schedule of Restructuring Plan Activity	'
	The following table summarizes the Q1 2013 Plan activity for the nine months ended September 28, 2014:
		Severance
		(In thousands)
	Balance at December 29, 2013	$	208
	Change in estimates	(208		)
	Balance at September 28, 2014	$	—

Interest_and_Other_Expense_Inc1

Interest and Other Expense (Income), Net (Tables)	9 Months Ended
	Sep. 28, 2014
Other Income and Expenses [Abstract]	'
Interest and Other Expense (Income), Net	'
	Interest and other expense, net, consisted of the following:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Interest income	$	(130	)	$	(119	)	$	(375	)	$	(288	)
	Interest expense	8,909			11,704			27,207			35,310
	Other expense, net	2,187			755			4,387			2,223
	Total interest and other expense, net	$	10,966		$	12,340		$	31,219		$	37,245

Inventories_Net_Tables

Inventories, Net (Tables)	9 Months Ended
	Sep. 28, 2014
Inventory Disclosure [Abstract]	'
Schedule of Net Inventories	'
	Inventories as of September 28, 2014 and December 29, 2013 consisted of the following:
		September 28,		December 29,
		2014		2013
		(In thousands)
	Raw materials	$	98,737	$	92,713
	Work in progress	17,450		15,505
	Finished goods	165,430		152,640
	Total inventories, net	$	281,617	$	260,858

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	9 Months Ended
	Sep. 28, 2014
Earnings Per Share [Abstract]	'
Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations	'
	The following table reconciles the number of shares utilized in the earnings per share calculations:
		Three Months Ended		Nine Months Ended
		September 28,	September 29,	September 28,	September 29,
		2014	2013	2014	2013
		(In thousands)
	Number of common shares—basic	112,646	111,827	112,662	112,285
	Effect of dilutive securities:
	Stock options	870	997	964	987
	Restricted stock awards	243	291	210	244
	Number of common shares—diluted	113,759	113,115	113,836	113,516
	Number of potentially dilutive securities excluded from calculation due to antidilutive impact	482	465	480	493

Industry_Segment_Information_T

Industry Segment Information (Tables)	9 Months Ended
	Sep. 28, 2014
Segment Reporting [Abstract]	'
Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations	'
	Revenue and operating income (loss) by operating segment, excluding discontinued operations, are shown in the table below:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Human Health
	Product revenue(1)	$	237,312		$	227,167		$	721,449		$	682,164
	Service revenue	64,213			63,040			185,770			184,256
	Total revenue	301,525			290,207			907,219			866,420
	Operating income from continuing operations	45,033			44,659			141,737			101,100
	Environmental Health
	Product revenue	128,621			128,578			391,578			394,225
	Service revenue	111,903			103,315			330,032			305,071
	Total revenue	240,524			231,893			721,610			699,296
	Operating income from continuing operations(1)	21,596			21,896			73,967			61,922
	Corporate
	Operating loss from continuing operations(2) (3)	(7,853		)	(8,601		)	(35,529		)	(28,158		)
	Continuing Operations
	Product revenue	365,933			355,745			1,113,027			1,076,389
	Service revenue	176,116			166,355			515,802			489,327
	Total revenue	542,049			522,100			1,628,829			1,565,716
	Operating income from continuing operations	58,776			57,954			180,175			134,864
	Interest and other expense, net (see Note 5)	10,966			12,340			31,219			37,245
	Income from continuing operations before income taxes	$	47,810		$	45,614		$	148,956		$	97,619
	____________________________
	(1)	In the third quarter of fiscal year 2014, the Company settled litigation and entered into a fully paid license related to the Company's microfluidics technology licensing program. The Company has allocated the proceeds of this license between revenue and litigation settlement using the residual method and concluded that the litigation settlement had no value. The Company has no future performance obligations associated with this license. The Company recognized revenue of $7.5 million in cash from the license within the Human Health segment. Also within the Human Health segment, the Company recognized revenue of $2.6 million in other consideration resulting from concurrent modifications to an existing collaboration agreement.
	(2)	Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax gain of $0.1 million for each of the nine months ended September 28, 2014 and September 29, 2013. There were no expenses related to the mark-to-market adjustment on postretirement benefit plans for either the three months ended September 28, 2014 or September 29, 2013.
	(3)	In 2002, Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, “Enzo”) filed a complaint that alleged that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and in the third quarter of fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded during the second quarter of fiscal year 2014. In addition, $3.4 million of expenses were incurred and recorded in preparation for the trial during the six months ended June 29, 2014.

Stockholders_Equity_Tables

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 28, 2014
Stockholders' Equity Note [Abstract]	'
Components of Accumulated Other Comprehensive Loss	'
	The components of accumulated other comprehensive income consisted of the following:
		September 28,			December 29,
		2014			2013
		(In thousands)
	Foreign currency translation adjustments	$	46,687		$	76,283
	Unrecognized prior service costs, net of income taxes	1,429			1,429
	Unrealized net losses on securities, net of income taxes	(163		)	(121		)
	Accumulated other comprehensive income	$	47,953		$	77,591

Stock_Plans_Tables

Stock Plans (Tables)	9 Months Ended
	Sep. 28, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Summary of Total Compensation Recognized Related to Outstanding Equity Awards	'
	The following table summarizes total pre-tax compensation expense recognized related to the Company’s stock options, restricted stock, restricted stock units, performance units and stock grants, net of estimated forfeitures, included in the Company’s condensed consolidated statements of operations for the three and nine months ended September 28, 2014 and September 29, 2013:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Cost of product and service revenue	$	386		$	337		$	1,056		$	958
	Research and development expenses	39			203			400			629
	Selling, general and administrative expenses	2,025			3,241			10,313			9,836
	Total stock-based compensation expense	$	2,450		$	3,781		$	11,769		$	11,423
Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model	'
	The Company’s weighted-average assumptions used in the Black-Scholes option pricing model were as follows:
		Three and Nine Months Ended
		September 28,		September 29,
		2014		2013
	Risk-free interest rate	1.5	%	0.9	%
	Expected dividend yield	0.7	%	0.8	%
	Expected lives	5 years		5 years
	Expected stock volatility	30.9	%	38.5	%
Summary of Stock Option Activity	'
	The following table summarizes stock option activity for the nine months ended September 28, 2014:
		Number		Weighted-			Weighted-Average		Total
		of		Average Exercise			Remaining		Intrinsic
		Shares		Price			Contractual Term		Value
		(In thousands)					(In years)		(In millions)
	Outstanding at December 29, 2013	3,494		$	23.34
	Granted	520		43.12
	Exercised	(889	)	23.55
	Canceled	(4	)	20.97
	Forfeited	(108	)	34.85
	Outstanding at September 28, 2014	3,013		$	26.28		3.6		$	58.2
	Exercisable at September 28, 2014	2,033		$	21.46		2.6		$	49.1
	Vested and expected to vest in the future	2,972		$	26.18		3.5		$	57.8
Summary of Restricted Stock Award Activity	'
	The following table summarizes restricted stock award activity for the nine months ended September 28, 2014:
		Number of		Weighted-
		Shares		Average
				Grant-
				Date Fair
				Value
		(In thousands)
	Nonvested at December 29, 2013	649		$	29.24
	Granted	242		42.69
	Vested	(256	)	27.68
	Forfeited	(67	)	33.35
	Nonvested at September 28, 2014	568		$	35.2

Goodwill_and_Intangible_Assets1

Goodwill and Intangible Assets, Net (Tables)	9 Months Ended
	Sep. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in the Carrying Amount of Goodwill	'
	The changes in the carrying amount of goodwill for the period ended September 28, 2014 from December 29, 2013 were as follows:
		Human			Environmental			Consolidated
		Health			Health
		(In thousands)
	Balance at December 29, 2013	$	1,648,332		$	494,788		$	2,143,120
	Foreign currency translation	(18,158		)	(5,443		)	(23,601		)
	Acquisitions and other	3,716			—			3,716
	Balance at September 28, 2014	$	1,633,890		$	489,345		$	2,123,235
Identifiable Intangible Asset Balances	'
	Identifiable intangible asset balances at September 28, 2014 and December 29, 2013 by category were as follows:
		September 28,			December 29,
		2014			2013
		(In thousands)
	Patents	$	39,971		$	39,591
	Less: Accumulated amortization	(26,560		)	(24,207		)
	Net patents	13,411			15,384
	Trade names and trademarks	34,846			35,809
	Less: Accumulated amortization	(17,803		)	(16,208		)
	Net trade names and trademarks	17,043			19,601
	Licenses	78,968			79,180
	Less: Accumulated amortization	(59,135		)	(52,930		)
	Net licenses	19,833			26,250
	Core technology	301,668			302,070
	Less: Accumulated amortization	(194,593		)	(169,326		)
	Net core technology	107,075			132,744
	Customer relationships	319,120			321,395
	Less: Accumulated amortization	(158,084		)	(132,833		)
	Net customer relationships	161,036			188,562
	IPR&D	10,388			9,483
	Less: Accumulated amortization	(2,904		)	(2,178		)
	Net IPR&D	7,484			7,305
	Net amortizable intangible assets	325,882			389,846
	Non-amortizing intangible assets:
	Trade names and trademarks	70,584			70,584
	Total	$	396,466		$	460,430

Warranty_Reserves_Tables

Warranty Reserves (Tables)	9 Months Ended
	Sep. 28, 2014
Product Warranties Disclosures [Abstract]	'
Warranty Reserve Activity	'
	A summary of warranty reserve activity for the three and nine months ended September 28, 2014 and September 29, 2013 is as follows:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Balance beginning of period	$	10,786		$	10,451		$	10,534		$	11,003
	Provision charged to income	4,187			4,160			12,596			12,673
	Payments	(4,154		)	(4,113		)	(12,509		)	(12,781		)
	Adjustments to previously provided warranties, net	(130		)	268			44			(54		)
	Foreign currency translation and acquisitions	(293		)	122			(269		)	47
	Balance end of period	$	10,396		$	10,888		$	10,396		$	10,888

Employee_Benefit_Plans_Tables

Employee Benefit Plans (Tables)	9 Months Ended
	Sep. 28, 2014
Compensation and Retirement Disclosure [Abstract]	'
Components of Net Periodic Benefit Cost (Credit)	'
	The following table summarizes the components of net periodic benefit cost (credit) for the Company’s various defined benefit employee pension and postretirement plans for the three and nine months ended September 28, 2014 and September 29, 2013:
		Defined Benefit						Postretirement
		Pension Benefits						Medical Benefits
		Three Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Service cost	$	1,030		$	916		$	24		$	28
	Interest cost	5,914			5,312			39			36
	Expected return on plan assets	(6,277		)	(6,261		)	(241		)	(241		)
	Amortization of prior service costs	(72		)	(67		)	—			—
	Net periodic benefit cost (credit)	$	595		$	(100	)	$	(178	)	$	(177	)
		Defined Benefit						Postretirement
		Pension Benefits						Medical Benefits
		Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Service cost	$	3,094		$	2,757		$	72		$	85
	Interest cost	17,761			15,925			116			107
	Expected return on plan assets	(18,820		)	(18,778		)	(723		)	(723		)
	Amortization of prior service	(214		)	(201		)	—			—
	Net periodic benefit cost (credit)	$	1,821		$	(297	)	$	(535	)	$	(531	)

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 28, 2014
Fair Value Disclosures [Abstract]	'
Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis	'
	The following tables show the assets and liabilities carried at fair value measured on a recurring basis as of September 28, 2014 and December 29, 2013 classified in one of the three classifications described above:
					Fair Value Measurements at September 28, 2014 Using:
		Total Carrying Value at September 28, 2014			Quoted Prices in			Significant Other			Significant
					Active Markets			Observable Inputs			Unobservable
					(Level 1)			(Level 2)			Inputs
											(Level 3)
		(In thousands)
	Marketable securities	$	1,391		$	1,391		$	—		$	—
	Foreign exchange derivative assets	220			—			220			—
	Foreign exchange derivative liabilities	(299		)	—			(299		)	—
	Contingent consideration	(1,286		)	—			—			(1,286		)
					Fair Value Measurements at December 29, 2013 Using:
		Total Carrying Value at December 29, 2013			Quoted Prices in			Significant Other			Significant
					Active Markets			Observable Inputs			Unobservable
					(Level 1)			(Level 2)			Inputs
											(Level 3)
		(In thousands)
	Marketable securities	$	1,319		$	1,319		$	—		$	—
	Foreign exchange derivative assets	293			—			293			—
	Foreign exchange derivative liabilities	(396		)	—			(396		)	—
	Contingent consideration	(4,926		)	—			—			(4,926		)
Reconciliation of Beginning and Ending Level 3 Net Liabilities	'
	A reconciliation of the beginning and ending Level 3 net liabilities for contingent consideration is as follows:
		Three Months Ended						Nine Months Ended
		September 28,			September 29,			September 28,			September 29,
		2014			2013			2014			2013
		(In thousands)
	Balance beginning of period	$	(3,430	)	$	(3,715	)	$	(4,926	)	$	(3,017	)
	Additions	—			—			—			(1,100		)
	Amounts paid and foreign currency translation	2,137			31			2,065			95
	Change in fair value (included within selling, general and administrative expenses)	7			826			1,575			1,164
	Balance end of period	$	(1,286	)	$	(2,858	)	$	(1,286	)	$	(2,858	)

Business_Combinations_Narrativ

Business Combinations (Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

12 Months Ended

3 Months Ended

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Jun. 29, 2014

Dec. 29, 2013

Jun. 30, 2013

Dec. 30, 2012

Sep. 28, 2014

Jul. 16, 2014

Sep. 28, 2014

Dec. 29, 2013

Dec. 28, 2014

Fiscal Year 2014 Acquisitions [Member]

Fiscal Year 2014 Acquisitions [Member]

Fiscal Year 2013 Acquisitions [Member]

Fiscal Year 2013 Acquisitions [Member]

Subsequent Event [Member]

Fiscal Year 2014 Acquisitions [Member]

Business Acquisition [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

Cash paid to the shareholders

'

'

'

'

'

'

'

'

$1,500,000

'

$400,000

$11,400,000

$16,700,000

Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt

'

'

'

'

'

'

'

'

'

-4,300,000

'

'

'

Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value

'

'

'

'

'

'

'

'

'

'

'

1,100,000

'

Total transaction costs

40,000

0

200,000

100,000

'

'

'

'

'

'

'

'

'

Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions

'

'

'1 year

'

'

'

'

'

'

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

26,400,000

'

26,400,000

'

'

'

'

'

'

'

'

2,200,000

'

Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value

$1,286,000

$2,858,000

$1,286,000

$2,858,000

$3,430,000

$4,926,000

$3,715,000

$3,017,000

'

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Maximum Period

'

'

'3 years

'

'

'

'

'

'

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Description

'

'

'Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.

'

'

'

'

'

'

'

'

'

'

Business_Combinations_Fair_Val

Business Combinations (Fair Values of the Business Combinations and Allocations for the Acquisitions Completed) (Details) (USD $)	Sep. 28, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Business Acquisition [Line Items]	'	'
Goodwill	$2,123,235	$2,143,120
Human Health [Member]	'	'
Business Acquisition [Line Items]	'	'
Goodwill	1,633,890	1,648,332
Environmental Health [Member]	'	'
Business Acquisition [Line Items]	'	'
Goodwill	$489,345	$494,788

Discontinued_Operations_Narrat

Discontinued Operations (Narrative) (Details) (USD $)	3 Months Ended			9 Months Ended
	Sep. 28, 2014	Jun. 29, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'
Pre-tax gain (loss) on disposal of business unit	($7,000)	'	($64,000)	($381,000)	$457,000
(Benefit from) provision for income taxes on discontinued operations and dispositions	-477,000	'	-257,000	-1,725,000	-1,173,000
Other Discontinued Operations [Member]	'	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'
Pre-tax gain (loss) on disposal of business unit	-7,000	'	-64,000	-124,000	-36,000
Photoflash Business [Member]	'	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'
Pre-tax gain (loss) on disposal of business unit	0	'	0	0	493,000
Microarray-based diagnostic testing laboratory in the United States [Member]	'	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'	'
Pre-tax gain (loss) on disposal of business unit	0	'	0	-257,000	0
Disposal Group, Including Discontinued Operations, Severance Costs	'	$1,000,000	'	'	'

Discontinued_Operations_Schedu

Discontinued Operations (Schedule of Gains and Losses on Disposition of Discontinued Operations) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Net gain (loss) on disposition of discontinued operations before income taxes	($7)	($64)	($381)	$457
Other Discontinued Operations [Member]	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Net gain (loss) on disposition of discontinued operations before income taxes	-7	-64	-124	-36
Photoflash Business [Member]	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Net gain (loss) on disposition of discontinued operations before income taxes	0	0	0	493
Microarray-based diagnostic testing laboratory in the United States [Member]	'	'	'	'
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Net gain (loss) on disposition of discontinued operations before income taxes	$0	$0	($257)	$0

Discontinued_Operations_Operat

Discontinued Operations (Operating Results of Discontinued Operations Prior to Disposition) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]	'	'	'	'
Disposal Group, Including Discontinued Operation, Revenue	$0	$2,177	$960	$7,236
Disposal Group, Including Discontinued Operations, Costs and Expenses	1,091	2,935	5,165	9,339
Loss from discontinued operations before income taxes	($1,091)	($758)	($4,205)	($2,103)

Restructuring_and_Lease_Charge2

Restructuring and Lease Charges, Net (Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

12 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

In Thousands, unless otherwise specified

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Dec. 29, 2013

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Sep. 28, 2014

Mar. 30, 2014

Mar. 30, 2014

Mar. 30, 2014

Mar. 30, 2014

Sep. 28, 2014

Dec. 29, 2013

Sep. 28, 2014

Dec. 29, 2013

Dec. 29, 2013

Sep. 28, 2014

Dec. 29, 2013

Sep. 28, 2014

Dec. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 28, 2014

Dec. 29, 2013

Jun. 30, 2013

Sep. 28, 2014

Dec. 29, 2013

Jun. 30, 2013

Dec. 29, 2013

Jun. 30, 2013

Sep. 28, 2014

Dec. 29, 2013

Sep. 28, 2014

Dec. 29, 2013

Sep. 28, 2014

Sep. 28, 2014

Mar. 31, 2013

Mar. 31, 2013

Mar. 31, 2013

Sep. 28, 2014

Dec. 29, 2013

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Q3 2014 Restructuring Plan [Member]

Q3 2014 Restructuring Plan [Member]

Q3 2014 Restructuring Plan [Member]

Q3 2014 Restructuring Plan [Member]

Q2 2014 Restructuring Plan [Member]

Q2 2014 Restructuring Plan [Member]

Q2 2014 Restructuring Plan [Member]

Q2 2014 Restructuring Plan [Member]

Q2 2014 Restructuring Plan [Member]

Q1 2014 Restructuring Plan [Member]

Q1 2014 Restructuring Plan [Member]

Q1 2014 Restructuring Plan [Member]

Q1 2014 Restructuring Plan [Member]

Q1 2014 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q3 2013 Restructuring Plan [Member]

Q3 2013 Restructuring Plan [Member]

Q3 2013 Restructuring Plan [Member]

Q3 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Previous restructuring and integration plans [Member]

Previous restructuring and integration plans [Member]

Previous restructuring and integration plans [Member]

Contract Termination [Member]

Human Health [Member]

Environmental Health [Member]

Severance [Member]

Human Health [Member]

Environmental Health [Member]

Severance [Member]

Severance [Member]

Human Health [Member]

Environmental Health [Member]

Severance [Member]

Severance [Member]

Human Health [Member]

Environmental Health [Member]

Severance [Member]

Severance [Member]

Facility Closing [Member]

Facility Closing [Member]

Human Health [Member]

Severance [Member]

Severance [Member]

Human Health [Member]

Human Health [Member]

Environmental Health [Member]

Severance [Member]

Severance [Member]

Facility Closing [Member]

Facility Closing [Member]

Facility Closing [Member]

Facility Closing [Member]

Human Health [Member]

Environmental Health [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Human Health [Member]

Environmental Health [Member]

Human Health [Member]

Human Health [Member]

Environmental Health [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Number of employees reduced

'

'

'

'

'

152

'

'

'

22

'

'

'

'

17

'

'

'

'

73

'

'

'

'

'

'

'

29

'

'

'

264

'

'

'

'

'

'

'

'

'

'

'

62

'

'

'

'

'

'

'

'

'

Restructuring and lease charges, net

$11,092

$1,124

$13,969

$23,681

'

'

$6,900

$6,200

$13,051

'

$500

$300

$735

'

'

$400

$200

$567

'

'

'

$8,200

$3,000

'

'

'

'

'

$500

'

'

'

'

'

$9,900

$600

$8,800

'

'

'

'

'

'

'

$2,300

$200

'

'

'

'

'

'

$1,500

Restructuring Reserve, Accrual Adjustment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

184

'

'

'

'

0

'

184

'

100

100

'

'

'

-208

'

-200

'

-800

-1,100

'

Payments for Restructuring

'

'

'

'

'

'

'

'

694

'

'

'

'

410

'

'

'

'

395

'

3,007

'

'

1,506

'

1,501

'

'

'

137

'

'

9,794

'

'

'

'

9,610

'

184

'

'

'

'

'

'

'

'

'

4,500

'

'

1,500

Remaining payments

$22,175

'

$22,175

'

$26,374

'

'

'

$12,357

'

'

'

'

$325

'

'

'

'

$172

$8,841

$5,834

'

'

$481

$1,987

$5,353

$6,854

'

'

$0

$137

'

$3,140

$12,750

'

'

'

$3,140

$12,750

$0

$0

'

'

'

'

'

$0

$208

'

$6,900

'

'

$400

Restructuring_and_Lease_Charge3

Restructuring and Lease Charges, Net (Schedule of Restructuring Plan Activity) (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

12 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

In Thousands, unless otherwise specified

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Jun. 29, 2014

Sep. 28, 2014

Mar. 30, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Jun. 29, 2014

Mar. 30, 2014

Dec. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Dec. 29, 2013

Sep. 28, 2014

Mar. 31, 2013

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Jun. 29, 2014

Mar. 30, 2014

Dec. 29, 2013

Jun. 30, 2013

Sep. 28, 2014

Mar. 31, 2013

Sep. 28, 2014

Q3 2014 Restructuring Plan [Member]

Q2 2014 Restructuring Plan [Member]

Q2 2014 Restructuring Plan [Member]

Q1 2014 Restructuring Plan [Member]

Q1 2014 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q3 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Previous restructuring and integration plans [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Severance [Member]

Facility Closing [Member]

Severance [Member]

Severance [Member]

Facility Closing [Member]

Severance [Member]

Q3 2014 Restructuring Plan [Member]

Q2 2014 Restructuring Plan [Member]

Q1 2014 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q3 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Previous restructuring and integration plans [Member]

Q3 2014 Restructuring Plan [Member]

Q2 2014 Restructuring Plan [Member]

Q1 2014 Restructuring Plan [Member]

Q4 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q2 2013 Restructuring Plan [Member]

Q1 2013 Restructuring Plan [Member]

Previous restructuring and integration plans [Member]

Facility Closing [Member]

Severance [Member]

Severance [Member]

Facility Closing [Member]

Severance [Member]

Restructuring Cost and Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring and lease charges, net

$11,092

$1,124

$13,969

$23,681

$13,051

$735

'

$567

'

'

'

'

'

'

'

'

'

'

$6,900

$500

$400

$8,200

$500

$9,900

$600

'

$2,300

'

'

$6,200

$300

$200

$3,000

$8,800

'

$200

'

Restructuring Reserve [Roll Forward]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at beginning of period

'

'

26,374

'

'

'

'

'

'

8,841

1,987

6,854

137

12,750

12,750

0

208

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring Reserve, Accrual Adjustment

'

'

'

'

'

'

'

'

'

'

'

'

'

184

0

184

-208

'

'

'

'

'

'

'

'

100

'

-200

-800

'

'

'

'

'

100

'

-1,100

Amounts paid and foreign currency translation

'

'

'

'

-694

'

-410

'

-395

-3,007

-1,506

-1,501

-137

-9,794

-9,610

-184

'

-4,500

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Balance at end of period

$22,175

'

$22,175

'

$12,357

'

$325

'

$172

$5,834

$481

$5,353

$0

$3,140

$3,140

$0

$0

$6,900

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest_and_Other_Expense_Inc2

Interest and Other Expense (Income), Net (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Other Income and Expenses [Abstract]	'	'	'	'
Interest income	($130)	($119)	($375)	($288)
Interest expense	8,909	11,704	27,207	35,310
Other expense, net	2,187	755	4,387	2,223
Total interest and other expense, net	$10,966	$12,340	$31,219	$37,245

Inventories_Net_Details

Inventories, Net (Details) (USD $)	Sep. 28, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$98,737	$92,713
Work in progress	17,450	15,505
Finished goods	165,430	152,640
Total inventories, net	$281,617	$260,858

Income_Taxes_Details

Income Taxes (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2013	Sep. 28, 2014	Sep. 29, 2013
Income Tax Contingency [Line Items]	'	'	'
Unrecognized tax benefits, gross	'	$32.10	'
Uncertain tax benefits if recognized that could affect the continuing operations effective tax rate	'	28.3	'
Uncertain tax positions including accrued interest, net of tax benefits and penalties, to be resolved within the next year	'	3	'
Open Tax Years by Major Tax Jurisdiction, Begin Date	'	'2006	'
Tax Adjustments, Settlements, and Unusual Provisions	'	-5.8	-15.6
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations	($9.40)	'	'

Debt_Details

Debt (Details) (USD $)

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

1 Months Ended

9 Months Ended

12 Months Ended

9 Months Ended

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Dec. 29, 2013

Oct. 25, 2011

Sep. 28, 2014

Dec. 29, 2013

Sep. 28, 2014

Sep. 28, 2014

Dec. 29, 2013

Dec. 29, 2013

Sep. 28, 2014

Sep. 30, 2012

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Line of Credit, Maturing January 8, 2019 [Member]

Line of Credit, Maturing January 8, 2019 [Member]

Line of Credit, Maturing December 16, 2016 [Member]

2021 Notes [Member]

2021 Notes [Member]

2021 Notes [Member]

2021 Notes [Member]

Other Debt Facilities [Member]

Other Debt Facilities [Member]

Financing Lease Obligations [Member]

Financing Lease Obligations [Member]

Financing Lease Obligations [Member]

Unsecured Revolving Credit Facility [Member]

Unsecured Revolving Credit Facility [Member]

Unsecured Revolving Credit Facility [Member]

Unsecured Revolving Credit Facility [Member]

Unsecured Revolving Credit Facility [Member]

Unsecured Revolving Credit Facility [Member]

Treasury Rate [Member]

Base Rate Option Two [Member]

Eurocurrency Rate [Member]

Line of Credit, Maturing January 8, 2019 [Member]

Line of Credit, Maturing January 8, 2019 [Member]

Line of Credit, Maturing January 8, 2019 [Member]

Line of Credit, Maturing January 8, 2019 [Member]

Base Rate Option Three [Member]

Base Rate Option Two [Member]

Eurocurrency Rate [Member]

Line of Credit Facility, Maximum Borrowing Capacity

'

$700,000,000

$700,000,000

$700,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unsecured revolving credit facility, expiry date

'

'

8-Jan-19

16-Dec-16

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Letters of credit issued and outstanding

'

12,200,000

12,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Remaining Borrowing Capacity

'

368,800,000

368,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest rate terms under amended senior unsecured revolving credit facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The interest rates under the senior unsecured revolving credit facility are based on the Eurocurrency rate or the base rate at the time of borrowing, plus a margin. The base rate is the higher of (i)B the rate of interest in effect for such day as publicly announced from time to time by JP Morgan Chase Bank, N.A. as its "prime rate," (ii)B the Federal Funds rate plus 50 basis points or (iii) one-month Libor plus 1.00%.

'

'

'

Weighted average interest rates under amended senior unsecured revolving credit facility

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The Eurocurrency margin as of SeptemberB 28, 2014 was 108 basis points. The weighted average Eurocurrency interest rate as of September 28, 2014 was 0.18%, resulting in a weighted average effective Eurocurrency rate, including the margin, of 1.26%.

'

'

'

Description of variable rate basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'Federal Funds

'Eurocurrency

'

'

'

'

Basis spread on variable rate

'

'

'

'

'

'

'

0.45%

'

'

'

'

'

'

'

'

1.00%

0.50%

1.08%

Weighted average Eurocurrency interest rate

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0.18%

Weighted average effective Eurocurrency rate, including the margin

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1.26%

Aggregate borrowings under the amended facility

'

319,000,000

319,000,000

397,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments of Financing Costs

1,845,000

1,800,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Interest Rate, Stated Percentage

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unsecured senior notes, face value

'

'

'

'

500,000,000

500,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Gross proceeds from the issuance of debt instrument

'

'

'

'

496,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Senior unsecured notes issuance as percentage of principal amount

'

'

'

'

99.37%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

3,100,000

2,400,000

2,600,000

'

'

'

'

'

'

'

'

'

'

'

'

Long-term Debt, Gross

'

'

'

'

'

497,600,000

497,400,000

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument maturity date

'

'

'

'

25-Nov-21

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of redemption of senior notes on or after August 15, 2021

'

'

'

'

100.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Percentage of redemption upon a change of control and a contemporaneous downgrade of the Notes

'

'

'

'

101.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial Fair Value of Other Long-term Debt Related to Financing Lease Obligations

'

'

'

'

'

'

'

'

'

'

'

'

29,300,000

'

'

'

'

'

'

Other Long-term Debt

'

'

'

'

'

'

'

'

3,600,000

0

40,300,000

39,500,000

'

'

'

'

'

'

'

Other Long-term Debt, Current

'

'

'

'

'

'

'

'

100,000

'

2,600,000

1,100,000

'

'

'

'

'

'

'

Other Long-term Debt, Noncurrent

'

'

'

'

'

'

'

'

3,500,000

'

37,700,000

38,500,000

'

'

'

'

'

'

'

Additional Financing Lease Obligations, funded by lessors

'

'

'

'

'

'

'

'

'

'

$11,500,000

'

'

'

'

'

'

'

'

Earnings_Per_Share_Schedule_of

Earnings Per Share (Schedule of Reconciliation of Number of Shares Utilized in Earnings Per Share Calculations) (Details)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Earnings Per Share [Abstract]	'	'	'	'
Number of common shares-basic	112,646	111,827	112,662	112,285
Effect of dilutive securities, Stock options	870	997	964	987
Effect of dilutive securities, Restricted stock	243	291	210	244
Number of common shares-diluted	113,759	113,115	113,836	113,516
Number of potentially dilutive securities excluded from calculation due to antidilutive impact	482	465	480	493

Industry_Segment_Information_I

Industry Segment Information Industry Segment Information Narrative (Details) (USD $)	3 Months Ended		9 Months Ended			3 Months Ended			6 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013	Dec. 29, 2013	Sep. 28, 2014	Jun. 29, 2014	Jun. 29, 2014	Jun. 29, 2014
			segments			Microfluidics Complaint [Member]	Microfluidics Complaint [Member]	Enzo Biochem, Inc. Complaint [Member]	Enzo Biochem, Inc. Complaint [Member]
Segment Reporting Information [Line Items]	'	'	'	'	'	'	'	'	'
Litigation Settlement, Amount	'	'	'	'	'	$0	'	'	'
Licenses Revenue	'	'	'	'	'	7.5	'	'	'
Other Revenue, Net	'	'	'	'	'	'	2.6	'	'
Defined Benefit Plan, Recognized Net (Gain) Loss on Mark-to-Market	0	0	-0.1	-0.1	'	'	'	'	'
Payments for Legal Settlements	7	'	'	'	'	'	'	'	'
Number of Operating Segment	'	'	2	'	'	'	'	'	'
Loss Contingency Accrual	'	'	'	'	3.7	'	'	'	'
Loss Contingency Accrual, Period Increase (Decrease)	'	'	'	'	'	'	'	3.3	'
Litigation Settlement, Expense	'	'	'	'	'	'	'	'	$3.40

Industry_Segment_Information_S

Industry Segment Information (Schedule of Sales and Operating Income by Operating Segment, Excluding Discontinued Operations) (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

6 Months Ended

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Dec. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Jun. 29, 2014

Jun. 29, 2014

Jun. 29, 2014

Human Health [Member]

Human Health [Member]

Human Health [Member]

Human Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Environmental Health [Member]

Corporate [Member]

Corporate [Member]

Corporate [Member]

Corporate [Member]

Microfluidics Complaint [Member]

Microfluidics Complaint [Member]

Enzo Biochem, Inc. Complaint [Member]

Enzo Biochem, Inc. Complaint [Member]

Segment Reporting [Abstract]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Defined Benefit Plan, Recognized Net (Gain) Loss on Mark-to-Market

$0

$0

($100,000)

($100,000)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Payments for Legal Settlements

7,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Segment Reporting Information [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Loss Contingency Accrual

'

'

'

'

3,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Litigation Settlement, Expense

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,400,000

Loss Contingency Accrual, Period Increase (Decrease)

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,300,000

'

Litigation Settlement, Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

0

'

'

'

Licenses Revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

7,500,000

'

'

'

Other Revenue, Net

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,600,000

'

'

Revenue

542,049,000

522,100,000

1,628,829,000

1,565,716,000

'

301,525,000

290,207,000

907,219,000

866,420,000

240,524,000

231,893,000

721,610,000

699,296,000

'

'

'

'

'

'

'

'

Operating income (loss) from continuing operations

58,776,000

57,954,000

180,175,000

134,864,000

'

45,033,000

44,659,000

141,737,000

101,100,000

21,596,000

[1]

21,896,000

73,967,000

[1]

61,922,000

-7,853,000

[2]

-8,601,000

[2]

-35,529,000

[2],[3]

-28,158,000

[2]

'

'

'

'

Interest and other expense, net

10,966,000

12,340,000

31,219,000

37,245,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Income from continuing operations before income taxes

47,810,000

45,614,000

148,956,000

97,619,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sales Revenue, Goods, Net

365,933,000

355,745,000

1,113,027,000

1,076,389,000

'

237,312,000

[1]

227,167,000

721,449,000

[1]

682,164,000

128,621,000

128,578,000

391,578,000

394,225,000

'

'

'

'

'

'

'

'

Sales Revenue, Services, Net

$176,116,000

$166,355,000

$515,802,000

$489,327,000

'

$64,213,000

$63,040,000

$185,770,000

$184,256,000

$111,903,000

$103,315,000

$330,032,000

$305,071,000

'

'

'

'

'

'

'

'

[1]

In the third quarter of fiscal year 2014, the Company settled litigation and entered into a fully paid license related to the Company's microfluidics technology licensing program. The Company has allocated the proceeds of this license between revenue and litigation settlement using the residual method and concluded that the litigation settlement had no value. The Company has no future performance obligations associated with this license. The Company recognized revenue of $7.5 million in cash from the license within the Human Health segment. Also within the Human Health segment, the Company recognized revenue of $2.6 million in other consideration resulting from concurrent modifications to an existing collaboration agreement.

[2]

Activity related to the mark-to-market adjustment on postretirement benefit plans has been included in the Corporate operating loss from continuing operations, and in the aggregate constituted a pre-tax gain of $0.1 million for each of the nine months ended SeptemberB 28, 2014 and SeptemberB 29, 2013. There were no expenses related to the mark-to-market adjustment on postretirement benefit plans for either the three months ended SeptemberB 28, 2014 or SeptemberB 29, 2013.

[3]

In 2002, Enzo Biochem, Inc. and Enzo Life Sciences, Inc. (collectively, bEnzob) filed a complaint that alleged that the Company separately and together with other defendants breached distributorship and settlement agreements with Enzo, infringed Enzo's patents, engaged in unfair competition and fraud, and committed torts against Enzo by, among other things, engaging in commercial development and exploitation of Enzo's patented products and technology. The Company entered into a settlement agreement with Enzo dated June 20, 2014 and in the third quarter of fiscal year 2014 paid $7.0 million into a designated escrow account to resolve this matter, of which $3.7 million had been accrued in previous years and $3.3 million was recorded during the second quarter of fiscal year 2014. In addition, $3.4 million of expenses were incurred and recorded in preparation for the trial during the six months ended June 29, 2014.

Stockholders_Equity_Narrative_

Stockholders' Equity (Narrative) (Details) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

In Millions, except Share data, unless otherwise specified

Sep. 28, 2014

Jun. 29, 2014

Mar. 30, 2014

Dec. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Mar. 31, 2013

Sep. 28, 2014

Sep. 29, 2013

Oct. 24, 2012

Dec. 28, 2014

Oct. 23, 2014

Subsequent Event [Member]

Subsequent Event [Member]

Schedule of Shareholders' Equity [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, before Tax

'

'

'

'

'

'

'

'

($1.50)

'

'

'

Other Comprehensive Income (Loss), Reclassification Adjustment on Derivatives Included in Net Income, Tax

'

'

'

'

'

'

'

'

0.6

'

'

'

Stock repurchase program, number of shares authorized to be repurchased

'

'

'

'

'

'

'

'

'

6,000,000

'

8,000,000

Number of common stock repurchased in open market

'

'

'

'

'

'

'

800,000

'

'

'

'

Stock Repurchased During Period, Value

'

'

'

'

'

'

'

34.8

'

'

'

'

Stock repurchase program, number of shares remained available for repurchase

1,700,000

'

'

'

'

'

'

1,700,000

'

'

'

'

Repurchased Common Shares For Activity Pursuant to Equity Incentive Plans

'

'

'

'

'

'

'

97,774

'

'

'

'

Aggregate Cost of Repurchased Common Shares for Activity Pursuant to Equity Incentive Plans

'

'

'

'

'

'

'

4.2

'

'

'

'

Cash dividends (per share)

$0.07

$0.07

$0.07

$0.07

$0.07

$0.07

$0.07

'

'

'

$0.07

'

Dividends Payable, Amount

$7.90

'

'

'

'

'

'

$7.90

'

'

'

'

Stockholders_Equity_Components

Stockholders' Equity (Components Of Accumulated Other Comprehensive Loss) (Details) (USD $)	Sep. 28, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Stockholders' Equity Note [Abstract]	'	'
Foreign currency translation adjustments, net of income taxes	$46,687	$76,283
Unrecognized losses and prior service costs, net of income taxes	1,429	1,429
Unrealized net losses on securities, net of income taxes	-163	-121
Accumulated other comprehensive loss	$47,953	$77,591

Stock_Plans_Narrative_Details

Stock Plans (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013	Dec. 29, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Number of Former Stock-based Compensation Plans	'	'	1	'	'
Total income tax benefit recognized for stock-based compensation	$800,000	$1,200,000	$4,200,000	$3,600,000	'
Stock-based compensation costs capitalized as part of inventory	'	'	400,000	300,000	'
Options related excess tax benefit, classified as a financing cash activity	'	'	0	0	'
Number of Shares, Granted	'	0	520,000	'	'
Total pre-tax stock-based compensation expense	2,450,000	3,781,000	11,769,000	11,423,000	'
Employee Stock Purchase Plan [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Shares authorized under plan	5,000,000	'	5,000,000	'	'
Number of Shares, Granted	'	'	60,870	89,521	'
Weighted-average grant-date fair value of stock granted (per share)	'	'	$41.71	$30.51	'
Shares available for grant under employee stock purchase plan	1,000,000	'	1,000,000	'	'
Stock Awards [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Number of Shares, Granted	'	'	2,373	3,263	'
Weighted-average grant-date fair value of stock granted (per share)	'	'	$42.14	$30.65	'
Total pre-tax stock-based compensation expense	'	'	700,000	700,000	'
Performance Units [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Number of Shares, Granted	'	'	79,463	98,056	'
Weighted-average grant-date fair value of stock granted (per share)	'	'	$42.84	$34.06	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	'	'	19,667	28,515	'
Total pre-tax stock-based compensation expense	-200,000	1,000,000	1,600,000	1,900,000	'
Awards/units outstanding	252,012	'	252,012	'	'
Deferred Compensation Share-based Arrangements, Liability, Current and Noncurrent	4,200,000	'	4,200,000	'	'
Restricted Stock Awards [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Number of Shares, Granted	'	'	242,000	'	'
Weighted-average grant-date fair value of stock granted (per share)	$45.42	$36.11	$42.69	$33.74	'
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	'	'	67,000	'	'
Fair value of restricted stock awards vested	100,000	400,000	7,100,000	7,600,000	'
Total pre-tax stock-based compensation expense	1,600,000	1,700,000	5,500,000	5,600,000	'
Awards/units outstanding	568,000	'	568,000	'	649,000
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	11,700,000	'	11,700,000	'	'
Weighted-average period for recognition of unrecognized compensation cost, years	'	'	'1 year 5 months	'	'
Stock Options [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Weighted-average grant-date fair value of options	$12.78	'	$11.86	$10.82	'
Total intrinsic value of options exercised	1,900,000	6,200,000	19,600,000	10,300,000	'
Cash received from option exercises	'	'	20,900,000	15,300,000	'
Total pre-tax stock-based compensation expense	1,000,000	1,100,000	3,900,000	3,200,000	'
Total unrecognized compensation cost, net of estimated forfeitures, related to nonvested stock, granted	$7,100,000	'	$7,100,000	'	'
Weighted-average period for recognition of unrecognized compensation cost, years	'	'	'1 year 11 months	'	'
2009 Incentive Plan [Member]	'	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'	'
Shares authorized under plan	10,000,000	'	10,000,000	'	'

Stock_Plans_Summary_of_Total_C

Stock Plans (Summary of Total Compensation Recognized Related to Outstanding Stock Options) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total pre-tax stock-based compensation expense	$2,450	$3,781	$11,769	$11,423
Cost of sales [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total pre-tax stock-based compensation expense	386	337	1,056	958
Research and development expenses [Member ]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total pre-tax stock-based compensation expense	39	203	400	629
Selling, general and administrative and other expenses [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Total pre-tax stock-based compensation expense	$2,025	$3,241	$10,313	$9,836

Stock_Plans_WeightedAverage_As

Stock Plans (Weighted-Average Assumptions Used in the Black-Scholes Option Pricing Model) (Details)	9 Months Ended
	Sep. 28, 2014	Sep. 29, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'	'
Risk-free interest rate	1.50%	0.90%
Expected dividend yield	0.70%	0.80%
Expected lives, years	'5 years	'5 years
Expected stock volatility	30.90%	38.50%

Stock_Plans_Summary_of_Stock_O

Stock Plans (Summary of Stock Option Activity) (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, except Share data in Thousands, unless otherwise specified	Sep. 29, 2013	Sep. 28, 2014
Stock option activity	'	'
Number of Shares, Outstanding at beginning of period	'	3,494
Number of Shares, Granted	0	520
Number of Shares, Exercised	'	-889
Number of Shares, Canceled	'	-4
Number of Shares, Forfeited	'	-108
Number of Shares, Outstanding at end of period	'	3,013
Number of Shares, Exercisable at end of period	'	2,033
Number of Shares, Vested and expected to vest in the future	'	2,972
Weighted-Average Price, Outstanding at beginning of period	'	$23.34
Weighted-Average Price, Granted	'	$43.12
Weighted-Average Price, Exercised	'	$23.55
Weighted-Average Price, Canceled	'	$20.97
Weighted-Average Price, Forfeited	'	$34.85
Weighted-Average Price, Outstanding at end of period	'	$26.28
Weighted-Average Price, Exercisable at end of period	'	$21.46
Weighted-Average Price, Vested and expected to vest in the future	'	$26.18
Weighted-Average Remaining Contractual Term in Years, Outstanding at end of period	'	'3 years 7 months
Weighted-Average Remaining Contractual Term in Years, Exercisable at end of period	'	'2 years 7 months
Weighted-Average Remaining Contractual Term in Years, Vested and expected to vest in the future	'	'3 years 6 months
Total Intrinsic Value, Outstanding at end of period	'	$58.20
Total Intrinsic Value, Exercisable at end of period	'	49.1
Total Intrinsic Value, Vested and expected to vest in the future	'	$57.80

Stock_Plans_Summary_of_Restric

Stock Plans (Summary of Restricted Stock Award Activity) (Details) (Restricted Stock Awards [Member], USD $)	3 Months Ended		9 Months Ended
	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Restricted Stock Awards [Member]	'	'	'	'
Restricted stock award activity	'	'	'	'
Number of Shares, Nonvested at beginning of period	'	'	649,000	'
Number of Shares, Granted	'	'	242,000	'
Number of Shares, Vested	'	'	-256,000	'
Number of Shares, Forfeited	'	'	-67,000	'
Number of Shares, Nonvested at end of period	568,000	'	568,000	'
Weighted-Average Grant-Date Fair Value, Nonvested at beginning of period	'	'	$29.24	'
Weighted-Average Grant-Date Fair Value, Granted	$45.42	$36.11	$42.69	$33.74
Weighted-Average Grant-Date Fair Value, Vested	'	'	$27.68	'
Weighted-Average Grant-Date Fair Value, Forfeited	'	'	$33.35	'
Weighted-Average Grant-Date Fair Value, Nonvested at end of period	$35.20	'	$35.20	'

Goodwill_and_Intangible_Assets2

Goodwill and Intangible Assets, Net (Narrative) (Details) (USD $)	3 Months Ended		9 Months Ended			9 Months Ended
	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013	Dec. 29, 2013	Sep. 28, 2014	Sep. 28, 2014	Jan. 01, 2014	Jan. 01, 2014
						Minimum [Member]	Maximum [Member]	Reporting units where FV exceeded CV by more than 90% [Domain]	Reporting Unit FV exceed CV by approximately 11% [Domain]
Goodwill and Intangible Assets Net [Line Items]	'	'	'	'	'	'	'	'	'
Reallocation of Goodwill Resulting from Realignment Within Operating Segments	$220,300,000	'	$220,300,000	'	'	'	'	'	'
Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount	20.00%	'	20.00%	'	'	'	'	90.00%	11.00%
Goodwill	2,123,235,000	'	2,123,235,000	'	2,143,120,000	'	'	'	796,300,000
Long-term terminal growth rates for reporting units	'	'	'	'	'	3.00%	6.00%	'	'
Discount rates for reporting units	'	'	'	'	'	10.00%	11.50%	'	'
Change in any one of the input assumptions for the various reporting units	'	'	10.00%	'	'	'	'	'	'
Total amortization expense related to finite-lived intangible assets	20,600,000	22,800,000	61,900,000	67,000,000	'	'	'	'	'
Future Amortization Expense, Year One	19,900,000	'	19,900,000	'	'	'	'	'	'
Future Amortization Expense, Year Two	69,200,000	'	69,200,000	'	'	'	'	'	'
Future Amortization Expense, Year Three	60,200,000	'	60,200,000	'	'	'	'	'	'
Future Amortization Expense, Year Four	50,700,000	'	50,700,000	'	'	'	'	'	'
Future Amortization Expense, Year Five	39,100,000	'	39,100,000	'	'	'	'	'	'
Finite-Lived Intangible Assets, Net	$325,882,000	'	$325,882,000	'	$389,846,000	'	'	'	'

Goodwill_and_Intangible_Assets3

Goodwill and Intangible Assets, Net (Changes in the Carrying Amount of Goodwill) (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014
Changes in the carrying amount of goodwill	'
Balance at beginning of period	$2,143,120
Foreign currency translation	-23,601
Goodwill, Acquisition, Earn Outs and Other Adjustments	3,716
Balance at end of period	2,123,235
Human Health [Member]	'
Changes in the carrying amount of goodwill	'
Balance at beginning of period	1,648,332
Foreign currency translation	-18,158
Goodwill, Acquisition, Earn Outs and Other Adjustments	3,716
Balance at end of period	1,633,890
Environmental Health [Member]	'
Changes in the carrying amount of goodwill	'
Balance at beginning of period	494,788
Foreign currency translation	-5,443
Goodwill, Acquisition, Earn Outs and Other Adjustments	0
Balance at end of period	$489,345

Goodwill_and_Intangible_Assets4

Goodwill and Intangible Assets, Net (Identifiable Intangible Asset Balances) (Details) (USD $)	Sep. 28, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Net amortizable intangible assets	$325,882	$389,846
Totals	396,466	460,430
Patents [Member]	'	'
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Gross amortizable intangible assets	39,971	39,591
Less: Accumulated amortization	-26,560	-24,207
Net amortizable intangible assets	13,411	15,384
Trade Names And Trademarks [Member]	'	'
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Gross amortizable intangible assets	34,846	35,809
Less: Accumulated amortization	-17,803	-16,208
Net amortizable intangible assets	17,043	19,601
Non-amortizing intangible assets	70,584	70,584
Licensing Agreements [Member]	'	'
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Gross amortizable intangible assets	78,968	79,180
Less: Accumulated amortization	-59,135	-52,930
Net amortizable intangible assets	19,833	26,250
Core Technology [Member]	'	'
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Gross amortizable intangible assets	301,668	302,070
Less: Accumulated amortization	-194,593	-169,326
Net amortizable intangible assets	107,075	132,744
Customer Relationships [Member]	'	'
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Gross amortizable intangible assets	319,120	321,395
Less: Accumulated amortization	-158,084	-132,833
Net amortizable intangible assets	161,036	188,562
In-process Research and Development [Member]	'	'
Finite and Indefinite Lived Intangible Assets by Major Class [Line Items]	'	'
Gross amortizable intangible assets	10,388	9,483
Less: Accumulated amortization	-2,904	-2,178
Net amortizable intangible assets	$7,484	$7,305

Warranty_Reserves_Details

Warranty Reserves (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Warranty reserve activity	'	'	'	'
Balance beginning of period	$10,786	$10,451	$10,534	$11,003
Provision charged to income	4,187	4,160	12,596	12,673
Payments	-4,154	-4,113	-12,509	-12,781
Adjustments to previously provided warranties, net	-130	268	44	-54
Foreign currency translation and acquisitions	-293	122	-269	47
Balance end of period	$10,396	$10,888	$10,396	$10,888

Employee_Benefit_Plans_Compone

Employee Benefit Plans (Components of Net Periodic Benefit Cost (Credit)) (Details) (USD $)	3 Months Ended		9 Months Ended
	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Defined Benefit Pension Benefits [Member]	'	'	'	'
Components of net periodic benefit cost (credit)	'	'	'	'
Service cost	$1,030,000	$916,000	$3,094,000	$2,757,000
Interest cost	5,914,000	5,312,000	17,761,000	15,925,000
Expected return on plan assets	-6,277,000	-6,261,000	-18,820,000	-18,778,000
Amortization of prior service	-72,000	-67,000	-214,000	-201,000
Net periodic benefit cost (credit)	595,000	-100,000	1,821,000	-297,000
Foreign Pension Plans, Defined Benefit [Member]	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Defined Benefit Plan, Contributions by Employer	'	'	2,800,000	17,900,000
Postretirement Medical Benefits [Member]	'	'	'	'
Components of net periodic benefit cost (credit)	'	'	'	'
Service cost	24,000	28,000	72,000	85,000
Interest cost	39,000	36,000	116,000	107,000
Expected return on plan assets	-241,000	-241,000	-723,000	-723,000
Amortization of prior service	0	0	0	0
Net periodic benefit cost (credit)	-178,000	-177,000	-535,000	-531,000
United States Pension Plan of US Entity [Member]	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Defined Benefit Plan, Contributions by Employer	'	'	'	37,000,000
United Kingdom Pension Plans, Defined Benefit [Member]	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Defined Benefit Plan, Contributions by Employer	'	'	'	$10,000,000

Derivatives_And_Hedging_Activi1

Derivatives And Hedging Activities (Details)	9 Months Ended		12 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014	Sep. 28, 2014	Dec. 29, 2013	Sep. 28, 2014	Dec. 29, 2013	Sep. 29, 2013	Dec. 30, 2012
		European And Asian Currencies [Member]	European And Asian Currencies [Member]	Fair Value Hedging [Member]	Fair Value Hedging [Member]	Fair Value Hedging [Member]	Cash Flow Hedging [Member]
				USD ($)	USD ($)	USD ($)	EUR (€)
Derivative [Line Items]	'	'	'	'	'	'	'
Maximum maturity period for foreign exchange contracts, in months	'	'12 months	'	'	'	'	'
Notional Amount of Cash Flow Hedge Instruments	'	'	'	$127.20	$138.40	$110	€ 50
Duration of foreign currency derivative contract, days	'	'30 days	'30 days	'	'	'	'
Company's business conducted outside United States	60.00%	'	'	'	'	'	'

Fair_Value_Measurements_Narrat

Fair Value Measurements (Narrative) (Details) (USD $)

9 Months Ended

Sep. 28, 2014

Jun. 29, 2014

Dec. 29, 2013

Sep. 29, 2013

Jun. 30, 2013

Dec. 30, 2012

Sep. 28, 2014

Dec. 29, 2013

Sep. 28, 2014

Dec. 29, 2013

Oct. 25, 2011

Sep. 28, 2014

Dec. 29, 2013

Sep. 28, 2014

Line of Credit, Maturing January 8, 2019 [Member]

Line of Credit, Maturing December 16, 2016 [Member]

2021 Notes [Member]

2021 Notes [Member]

2021 Notes [Member]

Financing Lease Obligations [Member]

Financing Lease Obligations [Member]

Other Debt Facilities [Member]

Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High

$26,400,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value

1,286,000

3,430,000

4,926,000

2,858,000

3,715,000

3,017,000

'

'

'

'

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Description

'Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Maximum Period

'3 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Business Combination, Contingent Consideration Arrangements, Weighted Average Period

'1 year 0 months

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of Credit Facility, Maximum Borrowing Capacity

'

'

'

'

'

'

700,000,000

700,000,000

'

'

'

'

'

'

Revolving credit facility outstanding balance

'

'

'

'

'

'

319,000,000

397,000,000

'

'

'

'

'

'

Unsecured senior notes, face value

'

'

'

'

'

'

'

'

500,000,000

'

500,000,000

'

'

'

Long-term Debt, Gross

'

'

'

'

'

'

'

'

497,600,000

497,400,000

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

'

'

'

'

2,400,000

2,600,000

3,100,000

'

'

'

Unsecured senior notes, fair value

'

'

'

'

'

'

'

'

$539,700,000

$513,000,000

'

$39,500,000

$40,300,000

$3,600,000

Fair_Value_Measurements_Assets

Fair Value Measurements (Assets and Liabilities Carried at Fair Value Measured on a Recurring Basis) (Details) (Fair Value, Measurements, Recurring [Member], USD $)	Sep. 28, 2014	Dec. 29, 2013
In Thousands, unless otherwise specified
Carrying (Reported) Amount, Fair Value Disclosure [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value Of Contingent Consideration Measured On Recurring Basis	($1,286)	($4,926)
Foreign exchange derivative liabilities, net	-299	-396
Marketable securities	1,391	1,319
Foreign exchange derivative assets, net	-220	-293
Quoted Prices In Active Markets (Level 1) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value Of Contingent Consideration Measured On Recurring Basis	0	0
Foreign exchange derivative liabilities, net	0	0
Marketable securities	1,391	1,319
Foreign exchange derivative assets, net	0	0
Significant Other Observable Inputs (Level 2) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value Of Contingent Consideration Measured On Recurring Basis	0	0
Foreign exchange derivative liabilities, net	-299	-396
Marketable securities	0	0
Foreign exchange derivative assets, net	-220	-293
Significant Unobservable Inputs (Level 3) [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Fair Value Of Contingent Consideration Measured On Recurring Basis	-1,286	-4,926
Foreign exchange derivative liabilities, net	0	0
Marketable securities	0	0
Foreign exchange derivative assets, net	$0	$0

Fair_Value_Measurements_Reconc

Fair Value Measurements (Reconciliation of Beginning and Ending Level 3 Net Liabilities) (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Fair Value Disclosures [Abstract]	'	'	'	'
Balance beginning of period	($3,430)	($3,715)	($4,926)	($3,017)
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases	0	0	0	-1,100
Payments	2,137	31	2,065	95
Change in fair value (included within selling, general and administrative expenses)	7	826	1,575	1,164
Balance end of period	($1,286)	($2,858)	($1,286)	($2,858)

Leases_Details

Leases (Details) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013	Sep. 28, 2014	Dec. 29, 2013	Aug. 22, 2013
Leases [Abstract]	'	'	'	'
Sale Leaseback Transaction, Date	'8/22/2013	'	'	'
Sale Leaseback Transaction, Gross Proceeds	$47.60	'	'	'
Sale Leaseback Transaction, Lease Terms	'P15Y	'	'	'
Sale Leaseback Transaction, Description of Accounting for Leaseback	'The lease is accounted for as an operating lease and the excess of the net proceeds over the net carrying amount of the property are being amortized on a straight-line basis over the initial lease term of 15 years.	'	'	'
Sale Leaseback Transaction, Deferred Gain, Gross	'	'	'	26.5
Sale Leaseback Transaction, Cumulative Gain Recognized	'	1.3	'	'
Sale Leaseback Transaction, Deferred Gain, Net	'	$24.50	$25.90	'

Contingencies_Details

Contingencies (Details) (USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014	Dec. 29, 2013
	years
Commitments and Contingencies Disclosure [Abstract]	'	'
Management's estimate of total cost of ultimate disposition	$12.30	$13.50
Number of years over which estimated environmental cost will be paid	10	'